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3Abstract
Ether lipids form a specialized class of lipids that are characterized by an O-alkyl bond at the sn-1
position of their glycerol backbone. The initial steps of their biosynthesis take place in the 
peroxisome. Among ether lipids, plasmalogens take on a dominant role. They perform important 
physiological functions, for example as constituents of cellular membranes or as scavengers of 
radicals. In humans, the lack of ether lipids, evoked by genetic defects concerning peroxisomal 
enzymes crucial for their biosynthesis, causes a fatal disease, rhizomelic chondrodysplasia punctata 
(RCDP). Recent research has also identified a subpopulation of glycosylphosphatidylinositol (GPI) 
anchors, a posttranslational modification that targets proteins to the outer surface of the cell 
membrane, as an ether lipid. Proteins associated with the membrane by GPI anchorage are recruited 
to specialized domains called membrane rafts, tightly packed assemblies, which are also enriched in 
plasmalogens. These microdomains constitute important platforms for various cellular processes like 
signal transduction or membrane trafficking. Thus, ether lipids might in many respects be essential 
for membrane composition. However, the exact role of these lipids in membranes and membrane 
subdomains has not yet been elucidated. 
In the present study, the use of human RCDP fibroblasts with major and minor amounts of residual 
plasmalogens allows for a comprehensive description of cellular responses to complete or partial 
depletion of ether lipids. Nano-electrospray ionization mass spectrometric analysis of these primary 
cultured human fibroblasts (performed in cooperation with the Heidelberg University Biochemistry 
Center) shows that the cells compensate for the loss of plasmalogens by increasing the synthesis of 
other phospholipids, namely phosphatidylethanolamines, which share the head group 
(ethanolamine) with the majority of plasmalogens. Supplementation of ether lipid-deficient cultures 
with plasmalogen precursors that already contain an ether linkage circumvents the peroxisomal 
steps of ether lipid synthesis. Interestingly, the resulting rescue of plasmalogen levels causes a 
corresponding decline in phosphatidylethanolamines, so that the amount of total ethanolamine 
phospholipids is kept constant in every circumstance. In addition, using immunofluorescence 
microscopy, the present study offers the proof that an O-alkyl chain is not necessarily required for 
the membrane anchoring of Thy-1, a GPI-anchored protein. However, sucrose density gradient 
centrifugation suggests a reorganization of membrane rafts upon depletion of ether lipids. 
Furthermore, some raft proteins, amongst others GPI-anchored proteins, exhibit changed amounts in 
western blot analysis and show an altered floating behavior in a density gradient. Additionally, 
preliminary experiments in murine myoblast cultures derived from ether lipid-deficient mice point to 
differences in the formation of the neuromuscular junction under conditions of ether lipid deficiency, 
which might also be a result of changed membrane properties.
Summarizing, in spite of compensatory mechanisms employed by human fibroblasts in response to 
ether lipid deficiency, a variety of changes, especially concerning cellular membranes, can be 
detected under these conditions. Owing to the importance of raft domains in several cellular 
activities, changed rafts might cause severe impairments in a multicellular organism, one of which 
could be the altered formation of the neuromuscular junction. Thus, the present findings suggest a 
crucial role of ether lipids in membrane raft composition and offer first insights into serious 
functional consequences in response to the depletion of these molecules. 
4Kurzfassung
Etherlipide bilden eine Klasse von Lipiden, die sich durch ihre O-Alkyl-Bindung an der sn-1-Position 
ihres Glycerin-Rückgrats auszeichnen und deren erste Biosyntheseschritte im Peroxisom ablaufen. 
Plasmalogene, die wichtigsten Etherlipide, haben große physiologische Bedeutung, zum Beispiel als 
strukturgebende Moleküle in der Zellmembran oder als Radikalfänger. Ein Mangel an Etherlipiden, 
der durch Mutationen in den entsprechenden peroxisomalen Enzymen hervorgerufen wird, führt im 
Menschen zu einer schweren Krankheit, rhizomelischer Chondrodysplasia punctata (RCDP). Neueste 
Forschungsarbeiten zeigten, dass auch eine Untergruppe der GPI-Anker, einer posttranslationalen 
Modifikation, die Proteine an der Außenseite der Zellmembran verankert, eine Etherbindung 
beinhaltet und damit vom peroxisomalen Biosyntheseweg abhängig ist. GPI-verankerte Proteine 
werden innerhalb der Membran in kleine Subdomänen, so genannte „membrane rafts“, dirigiert. 
Letztere sind dicht gepackte Membranabschnitte, die auch besonders reich an Plasmalogenen sind 
und die eine entscheidende Rolle zum Beispiel in der Signaltransduktion spielen. Etherlipide dürften 
daher in mehrerlei Hinsicht entscheidend für den Aufbau von zellulären Membranen sein, jedoch 
sind ihre genaue Aufgabe und Wirkung noch unbekannt.
In der vorliegenden Arbeit werden unter Verwendung modernster Techniken primäre 
Hautfibroblasten von RCDP-Patienten mit größeren und kleinen Plasmalogen-Restmengen auf ihre 
Reaktion auf die Etherlipiddefizienz untersucht. Mittels Nano-Elektrospray-Ionisierungs-
Massenspektrometrie (nano-ESI-MS) kann gezeigt werden, dass das Fehlen der Plasmalogene durch 
die erhöhte Synthese anderer Phospholipide, der Phosphatidylethanolamine, die die gleiche 
Kopfgruppe (Ethanolamin) wie ein Großteil der Plasmalogene besitzen, kompensiert wird. In 
Zellkultur kann der Defekt in der peroxisomalen Etherlipid-Biosynthese umgangen werden, indem 
Vorläufermoleküle mit bereits vorhandener Etherbindung dem Medium beigemengt werden. 
Interessanterweise reagieren Fibroblasten auf die vermehrte Bildung von Plasmalogenen bei 
Verfügbarkeit einer solchen Substanz mit einer Reduktion von Phosphatidylethanolaminen. Das weist 
darauf hin, dass die insgesamte Menge an Ethanolamin-Phospholipiden unter allen Umständen 
konstant gehalten wird. Weiters wird in dieser Arbeit mit Hilfe von Immunfluoreszenzmikroskopie 
bewiesen, dass – zumindest im Falle des GPI-verankerten Proteins Thy-1 – eine O-Alkyl-Kette in GPI-
Ankern nicht zwingend für deren Membranassoziation erforderlich ist. Hingegen zeigt sich, dass die 
Menge an einzelnen Raft-Proteinen, unter anderem auch GPI-verankerten Proteinen, in Etherlipid-
defizienten Zellen verändert ist. Die Rafts weisen zusätzlich ein im Vergleich zu Kontrollzellen 
verändertes Flotationsverhalten in einem Saccharose-Dichtegradienten auf. Als mögliche funktionelle 
Konsequenz dieser Veränderungen können leicht verkleinerte Acetylcholinrezeptor-Cluster bei der 
Enstehung der neuromuskulären Synapse in vitro an Hand von Myotuben, isoliert aus Etherlipid-
defizienten Mäusen, nachgewiesen werden. 
Alles in allem werden von Etherlipid-defizienten Zellen zwar kompensatorische Mechanismen 
eingesetzt; diese können aber Veränderungen der Zellmembran, besonders der „membrane rafts“, 
nicht verhindern. Aufgrund der großen Bedeutung dieser Subdomänen ist es naheliegend, dass ihre 
Veränderung auch für den gesamten Organismus schwere Konsequenzen (wie vielleicht eine 
geänderte Bildung der neuromuskulären Synapse) nach sich zieht, was in dieser Arbeit gezeigt 
werden kann. 
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CHAPTER 1
1INTRODUCTION
1.1 Peroxisomes
1.1.1 General Background
Peroxisomes are single-membrane-bound organelles that fulfill a large variety of functions in nearly 
all eukaryotic cells. Originally being described as “microbodies” in electron micrograph pictures 
(Rhodin, 1958), their importance in various metabolic processes was soon discovered: Peroxisomes 
play major roles in the metabolism of reactive nitrogen and oxygen species, which includes the 
detoxification of hydrogen peroxide, the biosynthesis of ether phospholipids, bile acids and 
docosahexaenoic acid, and the degradation of pipecolic, phytanic and very long-chain fatty acids. In 
addition, they are – to a certain extent – also involved in the metabolism of glyoxylate, amino acids
and isoprenoids as well as the pentose phosphate pathway (Wanders and Waterham, 2006a). Not 
only have there been metabolic functions assigned to peroxisomes, very recently they have also been 
shown to offer signaling platforms for innate immune responses (Dixit et al., 2010).
The manifold functional importance of the peroxisome is additionally underlined by the fact that 
peroxisomal dysfunctions lead to severe inherited human disorders, which can be grouped into the 
peroxisome biogenesis disorders (PBDs) and the single peroxisomal enzyme/transporter deficiencies. 
PBDs involve 13 complementation groups with defects in different PEX genes1, the best-studied one 
being Zellweger (or cerebrohepatorenal) syndrome, which is characterized by complete absence of 
peroxisomes leading to severe symptoms like craniofacial and eye abnormalities, neuronal migration 
defects and hepatomegaly. The disease inhibits normal development and affected children usually 
die within the first year of life (Steinberg et al., 2006; Wilson et al., 1986). 
In patients suffering from peroxisomal single enzyme/transporter deficiencies, one of the metabolic 
pathways in the peroxisome is disrupted. Disorders range from defects in ether lipid biosynthesis 
(see chapter 1.2) or peroxisomal alpha- and beta-oxidation, for example X-linked 
adrenoleukodystrophy, the most common monogenetic peroxisomal disorder, to dysfunctions of 
glyoxylate metabolism (Wanders and Waterham, 2006b). 
1.1.2 Peroxisomal Import 
As peroxisomes do not contain any DNA themselves, proteins have to be imported post-
translationally into the pre-existing organelle (Lazarow and Fujiki, 1985). The import of peroxisomal 
matrix proteins is a complex process; currently, two different peroxisomal targeting signals (PTS), 
utilizing distinct pathways, are known to enable the uptake of matrix proteins into the organelle:
1 PEX genes encode peroxins, proteins that are essential for peroxisome biogenesis (Distel et al., 1996)Distel, B., Erdmann, R., Gould, S.J., Blobel, G., Cra ne, D.I., Cregg, J.M., Dodt, G., Fujiki, Y.,  
Goodman, J.M., Just, W.W. , et al. (1996). A unified nomenclature for peroxisome biogenesis fa ctors. J Cell Biol 135 , 1-3.
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In order for a protein to be imported into the peroxisome, a PTS motif has to be recognized by a 
soluble receptor protein in the cytosol.
Ø The most prevalent targeting sequence, the PTS1, consists of the tripeptide -SKL at the very 
carboxy terminus of a peroxisomal protein (Gould et al., 1989). In addition, many functional
variants of this sequence exist (Brocard and Hartig, 2006).
PTS1 is recognized by its cytosolic receptor Pex5p2, which is able to interact with the 
sequence via its six tetratricopeptide repeats in the C-terminal segment (Brocard et al., 
1994).
Ø A comparably minor part of proteins utilizes the PTS2 pathway to be imported into 
peroxisomes. PTS2 has been identified as a conserved nonapeptide of the consensus 
sequence [R/K]-[L/V/I]-X5-[H/Q]-[L/A]. It is located near the N-terminus of certain 
peroxisomal matrix proteins and – in contrast to PTS1 – is cleaved from the cargo protein 
after import (Swinkels et al., 1991). 
The receptor for PTS2 is Pex7p, a member of the WD-403 protein family (Marzioch et al., 
1994), which unlike Pex5p cannot act autonomously, but instead interacts with auxiliary 
proteins as for example PEX5L, the long variant of PEX5, in mammals (Braverman et al., 
1998). 
The two pathways converge at the outer face of the peroxisomal membrane, where the receptor-
cargo complexes bind to a docking machinery consisting of Pex13p and Pex14p (and Pex17p in 
yeasts), which themselves form a complex with other peroxins (Pex8p, Pex2p, Pex10p, Pex12p), 
jointly constituting the “importomer” (Agne et al., 2003; Rayapuram and Subramani, 2006). Receptor 
and cargo are then translocated across the membrane in a fashion that has not been fully elucidated, 
and the matrix protein is released from its receptor (Lanyon-Hogg et al., 2010). The latter is then 
recycled back into the cytosol or destined for degradation by the proteasome through
polyubiquitination (Platta et al., 2004). A summary of this complex process is depicted in Figure 1. 
In addition to these two pathways, peroxisomal membrane proteins are imported by a different 
strategy, whose exact mechanism is currently still under debate (Ma and Subramani, 2009). 
2 This annotation refers to yeast proteins. The process, however, is accomplished in a similar fashion by 
mammalian homologs.  
3 This name indicates the length of approximately 40 amino acids and the terminating dipeptide consisting of 
tryptophan (W) and aspartic acid (D).
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Figure 1: Import of proteins into the peroxisomal matrix (adapted from: Platta and Erdmann, 
2007). PTS motifs in peroxisomal matrix proteins are recognized by the respective receptors 
(Pex5p for PTS1, Pex7p for PTS2) and the receptor-cargo complex is shuttled across the 
peroxisomal membrane. In the peroxisome lumen (= matrix), the cargo protein is released from 
its receptor. The latter is then ubiquitinated and recycled into the cytosol (in case of 
monoubiquitination) or degraded by the proteasome (in case of polyubiquitination).
1.2 Plasmalogens and the Group of Ether Lipids
One of the most important pathways taking place in the peroxisome is the biosynthesis of ether 
phospholipids, of which plasmalogens constitute by far the largest group. 
Plasmalogens carry a glycerol backbone like other phospholipids (phosphatidylserine, -choline, -
ethanolamine, etc.) and are characterized by a vinyl ether bond4 – in contrast to the ester bond 
found in diacylglycerophospholipids – at the sn-1 position (for the structure of a classical 
plasmalogen species see Figure 2). The aliphatic moieties at the sn-1 position normally consist of 
C16:0, C18:0 or C18:1. In contrast, the sn-2 position is – especially in neurons – usually occupied by a 
polyunsaturated fatty acid (PUFA) of the n-6 or n-3 class (Han, 2005). At the sn-3 position, the 
glycerol backbone is linked via a phosphodiester bond to a head group, mainly ethanolamine or 
choline, although in rare cases also other species like inositol or serine have been described.
Plasmalogens are therefore referred to as plasmenylethanolamines (PL-PE) or plasmenylcholines (PL-
PC), respectively, whereas their ether linked counterparts, which do not harbor the characteristic 
vinyl bond, are named plasmanylethanolamines and -cholines. Plasmalogens have quite an unusual 
distribution in living organisms, as their existence has been shown in strictly anaerobic bacteria, but 
not in aerobic bacteria or fungi. However, in vertebrate and invertebrate animal species,
plasmalogens are very common. The following paragraphs will focus on characteristics of 
plasmalogens and ether lipids in mammals, though keeping in mind that their biosynthetic pathway 
in bacteria differs from the one in animals (Goldfine, 2010).
4 A cis double bond adjacent to the ether linkage
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Figure 2: Examples of phospholipid structures. (A) Plasmalogen (Plasmenyl-) (B) Non-
plasmalogen ether phospholipid (Plasmanyl-) (C) Non-ether phospholipid (Phosphatidyl-). The 
vinyl ether bond is the main characteristic of plasmalogens.
The abundance of plasmalogens varies strongly between different tissues and cell types with the 
highest amounts being present in brain, heart, spleen, lymphocytes, macrophages and 
polymorphonuclear leukocytes as opposed to the liver, in which only 5% of the ethanolamine 
phospholipids are plasmalogens. The distribution of head groups differs as well: brain myelin is highly 
enriched in ethanolamine plasmalogens, whereas cardiac muscle has a high content of choline 
plasmalogens (Nagan and Zoeller, 2001).
Biosynthesis of plasmalogens involves several organelles and comprises a series of steps (for an 
overview see Figure 3), the first of which take place in the peroxisome. In the initial reaction 
catalyzed by the peroxisomal matrix protein dihydroxyacetone phosphate acyltransferase (DAPAT, 
DHAPAT; encoded by the GNPAT gene), dihydroxyacetone phosphate (DHAP) is esterified with a fatty 
acid supplied by acyl-CoA, thereby generating acyl-DHAP. Whether the substrates for the DAPAT-
reaction, DHAP and acyl-CoA, are produced inside the peroxisome or shuttled into the organelle from 
the cytosol, is still unknown (Wanders and Brites, 2010). DAPAT is exclusively localized and stable 
within peroxisomes and is – as most other matrix proteins – targeted to the organelle by a PTS1 
sequence (Jones and Hajra, 1977; Thai et al., 1997). In the subsequent biosynthetic step, the ether 
bond is introduced by the second enzyme in the pathway, alkylglycerone phosphate synthase (AGPS; 
also known as: alkyl-dihydroxyacetone phosphate synthase, ADHAPS; encoded by the AGPS gene)
(Brown and Snyder, 1982; Hajra et al., 1988), using a long-chain fatty alcohol derived from dietary 
intake or generated at the outer face of the peroxisomal membrane (Burdett et al., 1991). AGPS has 
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been shown to be exclusively peroxisomal as well (Singh et al., 1993), forming a 210 kDa 
heterotrimeric complex with DAPAT in the peroxisomal matrix, which is essential for DAPAT stability 
(de Vet et al., 1999; Thai et al., 1997). In contrast to DAPAT, AGPS harbors a PTS2 guiding it to the 
peroxisome (de Vet et al., 1997). The last contribution of peroxisomes to the generation of ether
lipids is the enzyme acyl/alkyl-dihydroxyacetone phosphate reductase, which can be bound either to 
the peroxisomal membrane or the endoplasmic reticulum (ER) facing the cytosol and catalyzes the 
reduction of the keto group at the sn-2 position (Datta et al., 1990). All subsequent biosynthetic steps 
take place in the ER: a fatty acid is esterified with the sn-2 position by alkylglycerol-3-phosphate 
acyltransferase (AGPAT), the ethanolamine head group is introduced by the sequential activity of a 
phosphohydrolase and an ethanolamine phosphotransferase and finally the vinyl ether bond is 
??????????????????????????-alkyl desaturase (Brites et al., 2004). Plasmenylcholine is thought to be 
synthesized from plasmenylethanolamine via sn-2 and polar head group modifications (Lee et al., 
1991).
As plasmalogens account for ∼18% of the human phospholipid mass (Nagan and Zoeller, 2001), they 
have to be of great importance for the individual. However, the functions of these molecules have 
not yet been fully elucidated: 
Ø As plasmalogens contain very high levels of PUFAs compared with their diacyl phospholipid 
counterparts, they can be seen as storage depots of docosahexaenoic acid (DHA) or 
arachidonic acid (AA) (Ford and Gross, 1989; Gaposchkin and Zoeller, 1999), which can only 
to a low extent be synthesized de novo by humans and are essential for brain development 
and cognitive function. The storage function of plasmalogens is underlined by the fact that 
DHA levels are reduced in patients lacking ether lipids (Martinez, 1992).
Ø Plasmalogens are involved in several signal transduction processes: A plasmalogen-selective 
phospholipase A2 degrades plasmalogens (Hazen et al., 1990) releasing bioactive compounds 
like lysoplasmalogens, DHA and AA, the latter two being metabolized to eicosanoids, which 
serve as second messengers (Di Marzo, 1995; Yang et al., 1996). A role of plasmalogens in the 
regulation of protein kinase C (PKC) signaling has been proposed, as well (Nagan and Zoeller, 
2001).
Ø Initially, protection from reactive oxygen species was thought to be the main task 
accomplished by plasmalogens (Zoeller et al., 1988). This antioxidative function is 
demonstrated by the fact that the vinyl ether bond is able to scavenge oxygen radicals (Reiss 
et al., 1997); protection against iron-induced peroxidation is conferred by plasmalogens, too 
(Sindelar et al., 1999). In addition, enhanced lipid peroxidation in membranes was observed 
in cells with reduced plasmalogen biosynthesis. However, data are conflicting, as the opinion 
has emerged that plasmalogen oxidation might also be harmful to the organism by creating 
highly reactive compounds itself (Felde and Spiteller, 1995). Lessig and Fuchs therefore 
suggest that “the description of plasmalogens as “antioxidants” should be treated with care” 
(Lessig and Fuchs, 2009). 
Ø Plasmalogens serve as mediators of membrane dynamics and as important structural 
molecules of the plasma membrane (see also chapter 1.4). They have been shown to have a 
pronounced effect on membrane fluidity in a way that plasmalogen-containing membranes 
are less fluid and more ordered than membranes of plasmalogen-deficient cells (Hermetter 
et al., 1989). Besides, there is evidence for the fusogenic activity of plasmalogens (Glaser and 
Gross, 1994) suggesting a role of these molecules in membrane dynamics, e.g. in the course 
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of signal transduction or of synaptic transmission (Gorgas et al., 2006). This is also 
corroborated by the observation that human fibroblasts defective in ether lipid synthesis 
show impairments in the endocytotic cycle as well as changes in intracellular cholesterol 
homeostasis (Thai et al., 2001). 
Figure 3: Biosynthesis of plasmalogens. The first two steps take place in the peroxisome, the 
corresponding enzymes are highlighted. Biosynthesis further proceeds at the outer peroxisomal 
or ER membrane and is finalized in the ER. DAPAT, dihydroxyacetone phosphate acyltransferase; 
AGPS, alkyl-dihydroxyacetone phosphate synthase; AGPAT, alkylglycerol-3-phosphate 
acyltransferase; CDP, cytidine diphosphate; NAD(P), nicotinamide adenine dinucleotide 
(phosphate); DHAP, dihydroxyacetone phosphate
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Although plasmalogens constitute, by far, the most abundant group of ether lipids, there are other 
ether lipid molecules that follow the same biosynthetic pathway as plasmalogens: 
Ø Platelet-activating factor (PAF; 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) is an 
important signaling molecule in inflammatory reactions and, additionally, serves as mediator 
in many further physiological as well as pathological processes (Prescott et al., 2000; 
Stafforini et al., 2003). 
Ø Seminolipid, a sulfoglycolipid, makes up more than 90% of glycolipid in the testis and is a 
crucial factor in the process of spermatogenesis (Honke et al., 2004). 
Ø Very recently, the lipid moiety of the GPI anchor was shown to be – at least in some proteins
– an ether lipid as well (see chapter 1.3) (Kanzawa et al., 2009). 
A role of ether lipids, especially plasmalogens, has been implicated in a variety of human diseases, 
mainly because of the fact that changes in plasmalogen levels have been reported e.g. in Alzheimer’s 
disease (Han et al., 2001), Down syndrome (Murphy et al., 2000a), Niemann-Pick disease type C 
(Schedin et al., 1997) or ischemia (Ford et al., 1991). Not surprisingly, deficiency in ether lipid 
synthesis also accounts for some of the symptoms in various peroxisome biogenesis disorders. In 
addition, rhizomelic chondrodysplasia puncatata is a group of diseases that are mainly characterized 
by the loss of ether lipids and therefore highlight the importance of these lipids in the human body.
1.2.1 Rhizomelic Chondrodysplasia Punctata (RCDP)
Rhizomelic chondrodysplasia punctata is a rare, but very severe autosomal recessive disorder of 
peroxisome metabolism that affects around 1 in 100 000 individuals (Stoll et al., 1989). The clinical 
hallmarks of the disease include severe symmetrical shortening of proximal long bones (rhizomelia), 
bilateral cataracts, disturbed endochondral bone formation (chondrodysplasia punctata), severe 
contractures, cranial facial abnormalities as well as mental and growth retardation (Purdue et al., 
1999; Steinberg et al., 2006). Death of affected infants usually occurs in childhood (mainly because of 
respiratory failure) with many children dying in the first year of life and only 50% of patients or even 
less surviving to the age of 6 years (Moser et al., 1996; White et al., 2003). The course of the disease 
can be heterogeneous; some RCDP patients with mild phenotypes have been reported (Braverman et 
al., 2002; Motley et al., 2002; Nuoffer et al., 1994).
All RCDP patients share a common biochemical feature, which is a defect in ether lipid biosynthesis, 
but can be grouped on a genetic basis as follows: 
Ø RCDP type I, the most common subgroup, is caused by mutations in the PEX7 gene encoding 
peroxin 7 (PEX7, see chapter 1.1.2), which is the receptor for PTS2 containing proteins in 
humans (Braverman et al., 1997; Motley et al., 1997; Purdue et al., 1997). As a consequence 
of the genetic defect, proteins with a PTS2 – for example AGPS, one of the crucial enzymes in 
ether lipid biosynthesis – cannot be delivered to the peroxisome resulting in defects in ether 
lipid biosynthesis and ???? ?-oxidation of phytanic acid and a mild impairment in the 
degradation of very long-chain fatty acids (Hoefler et al., 1988; Schutgens et al., 1993). 
Ø Patients suffering from RCDP type II have a defect in DAPAT, the first enzyme in the ether 
lipid biosynthetic pathway, which leads to a complete inability to synthesize ether 
phospholipids. Phytanic acid levels were shown to be normal (Wanders et al., 1992).
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Ø RCDP type III is evoked by an isolated AGPS deficiency, due to which affected individuals
cannot synthesize plasmalogens and other ether lipids (Wanders et al., 1994).
RCDP types II and III are extremely rare with only a few patients reported. However, the fact that 
they share all the clinical symptoms with RCDP type I points towards ether lipids as being fully 
responsible for the severe disease course in all subgroups.
1.2.2 Mouse Models of Ether Lipid Deficiency
Several mouse models have been generated that resemble human RCDP and are, therefore, valuable 
tools in the elucidation of the molecular mechanisms, in which plasmalogens and ether lipids are 
involved. 
In 2003, the characterization of a DAPAT knockout (ko) mouse model was reported by Rodemer and 
collaborators (Rodemer et al., 2003). This mouse is viable, but it exhibits a striking phenotype due to 
its inability to synthesize ether lipids. Males are infertile because of an impairment in blood-testis 
barrier formation (Komljenovic et al., 2009). The mice show growth reduction and a high variability in 
lifespan with about 40% of pups dying within their first weeks of life. Other symptoms include ocular 
abnormalities with cataracts similar to those observed in RCDP, changes in membrane structure, and 
myelination defects in the cerebellum (Rodemer et al., 2003; Teigler et al., 2009).
In addition to the DAPAT knockout mouse, two different Pex7 mouse models have been established 
representing the severe and mild form of RCDP type I, respectively. The Pex7 knockout mouse is very
severely affected with only 30% of pups surviving past the weaning period. Dwarfism, hypotonia, 
cataracts, neuronal migration defects and delayed endochondral ossification can be observed and 
adult mice are infertile (Brites et al., 2003). 
The Pex7 hypomorphic mouse created by Braverman and collaborators produces residual levels of 
Pex7 transcript. These mice have a normal lifespan and are fertile, although plasmalogen levels are 
markedly reduced and the animals develop cataracts and dwarfism as observed in the complete 
knockout models of DAPAT and Pex7 deficiency (Braverman et al., 2010). 
Several mouse models also of Zellweger syndrome exist (Baes et al., 1997; Faust and Hatten, 1997; 
Maxwell et al., 2003), in which plasmalogen deficiency definitely accounts for some of the observed 
defects. However, as individual symptoms cannot be assigned to the lack of ether lipids in these 
Zellweger mice, the mouse models described above constitute better tools to study plasmalogen and 
ether lipid functions. 
1.3 GPI Anchor
1.3.1 General Background
In eukaryotic cells, there are many ways to modify proteins post-translationally. Several of these 
modifications, for example the addition of isoprenoids, fatty acids or cholesterol, aim at the 
attachment of proteins to membranes. Another type of lipid modification tethers proteins exclusively 
to the outer leaflet of the plasma membrane: the glycosylphosphatidylinositol (GPI) anchor. About
1% of all eukaryotic proteins and 10-20% of membrane proteins that enter the secretory pathway, 
have been reported to be attached to the membrane by a GPI anchor (Orlean and Menon, 2007). 
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However, this number is still increasing, as additional GPI-anchored proteins are identified. A wide 
variety of functions is fulfilled by these proteins, as for example cellular adhesion (by NCAM), signal 
transduction (by CD14) or intracellular protein sorting. Prominent examples of GPI-anchored proteins 
include the prion protein being famous as a trigger of Creutzfeldt-Jakob disease in humans, the 
complement regulators CD55 (decay-accelerating factor) and CD59, and a specific isoform of 
acetylcholinesterase, which plays an important role in synaptic transmission. The great importance of 
these proteins is further supported by the fact that an inability to synthesize GPI anchors is 
embryonically lethal in mammals (Kawagoe et al., 1996) and conditionally lethal in yeast (Leidich et 
al., 1994). 
The structure of the GPI anchor is extraordinarily complex and diverse given that its only confirmed 
biological function is membrane attachment (Paulick and Bertozzi, 2008). Nevertheless, all anchors so 
far investigated share the following core structure (for illustration see Figure 4): An ethanolamine 
links the anchor via an amide bond to the C-terminus of the protein. Further elements of the core 
structure include a certain sequence of sugar residues and phosphatidylinositol (Ikezawa, 2002).
Figure 4: Core structure of the GPI anchor (adapted from: Mayor & Riezman, 2004). Potential 
sites of lipid and sugar modifications are displayed; the lipid moiety can consist of diacyl- (as 
depicted here) or alkylacylglycerol. The position of a possible ether bond (instead of the ester 
bond in the picture) is indicated by a red arrow. DAG, diacylgylcerol (Mayor and Riezman, 2004)
Apart from this core structure, GPI anchors differ strongly from species to species according to their 
sugar modifications or lipid moieties (Fujita and Kinoshita, 2010). Although anchor structure has been 
extensively studied in S. cerevisiae or T. brucei as well, the work in the present thesis will exclusively 
focus on the mammalian GPI anchor. 
Sugar modifications in mammals usually have a characteristic pattern and will not be discussed in this 
context. The lipid moiety, however, can appear in two different shapes; these are either 
diacylglycerol or 1-alkyl-2-acylglycerol (alkylacylglycerol). In the former case, the sn-1 and sn-2
positions of glycerol are occupied by, usually saturated, fatty acids (C16 or C18 at sn-1; C18 at sn-2) 
(Kinoshita et al., 2008) except in erythrocytes, where fatty acids of the 20:4 type have been reported 
at sn-2 (Deeg et al., 1992; Rudd et al., 1997). In the latter case, the sn-1 position is connected via an 
ether bond to the saturated carbon chain; hence, this molecule is a classical ether lipid. At the sn-3
position, a phosphate group links the lipid moiety to inositol and the residual anchor. 
Although the existence of an ether bond in some GPI anchors has been known for quite a long time 
and the only known pathway of ether lipid biosynthesis involves the peroxisome (see chapter 1.2), 
the peroxisome dependency of GPI anchor biosynthesis has been under debate until 2009, when the 
absence of alkylacylglycerol containing GPI anchors in DAPAT-deficient CHO cells was shown 
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(Kanzawa et al., 2009). The latter finding led to a revision of the model for biosynthesis of GPI 
anchors (cf. Figure 5):
The first steps of the pathway take place at the cytoplasmic face of the ER membrane, where N-
acetylglucosamine (GlcNAc) is added to the starting product phosphatidylinositol (PI) and later de-N-
acetylated. By a not clearly defined mechanism, the resulting GlcN-PI flips to the luminal side of the 
ER membrane, where a palmitoyl chain is esterified with the inositol part. This is, where peroxisomes 
and the ether lipid synthesis pathway come into play: The lipid moiety of the GPI-precursor, which is 
almost exclusively diacylglycerol (Houjou et al., 2007), is then hypothesized to be exchanged to 
diradyl-PI5 consisting of a mixture of alkylacyl-PI and diacyl-PI. The alkylacyl moiety of GPI anchors 
has been proven to be derived from the peroxisomal ether lipid pathway (Fujita and Kinoshita, 2010; 
Kanzawa et al., 2009). After this lipid substitution, which is thought to be mediated by a
phospholipase C or D member (Kanzawa et al., 2009), different sugar moieties and 
phosphatidylethanolamine side chains are added to the precursor in a sequential manner. At this 
point, the immature GPI anchor is transferred to the protein, which is destined for GPI-anchoring by 
the presence of a certain signal peptide (Caras et al., 1987). Directly thereafter, GPI biosynthesis is 
finalized by some remodeling steps partly in the ER, partly after transport of the GPI-protein to the 
trans-Golgi network: The acyl chain is removed from the inositol ring, a process that has been shown 
to be crucial for GPI anchor functioning and therefore survival in mammals (Ueda et al., 2007). In 
addition, the glycan moiety is slightly modified and the unsaturated fatty acid at the sn-2 position of 
glycerol, which is derived from the original PI molecule, exchanged for a saturated one (Fujita and 
Kinoshita, 2010).
So far, the biological significance of the ether bond in the GPI lipid moiety is not known. However, 
many mammalian GPI-anchored proteins analyzed show a considerable proportion of 
alkylacylglycerol in their lipid moiety (Redman et al., 1994; Roberts et al., 1988; Rudd et al., 1997; 
Walter et al., 1990). From this, the justified question arises, why the cell would involve an additional 
organelle, namely the peroxisome, in the complex process of GPI biosynthesis, if it was not of utmost 
importance.
5 Radyl- indicates any acyl-, alkyl- or alkenyl- group.
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Figure 5: Biosynthesis of a GPI anchor. Step (5) constitutes the potential insertion of the ether 
lipid derived from a peroxisomal precursor. TA, transamidation; ID, inositol deacylation; GR, 
glycan remodeling; FR, fatty acid remodeling; EtNP, ethanolamine phosphate; GlcN, glucosamine; 
GlcNAc, N-acetylglucosamine; Dol-P-Man, dolichol-phosphate-mannose; PE, 
phosphatidylethanolamine (adapted from: Fujita and Kinoshita, 2010)
1.3.2 Thy-1 (CD90) 
Thymus cell antigen 1 (Thy-1, CD90), a small member of the immunoglobulin superfamily, was used 
as a “reference” GPI-anchored protein in the course of this study. It is expressed in a variety of 
different cell types including fibroblasts and (in humans preferentially adult) neurons as well as 
murine, but not human, T lymphocytes (Pont, 1987), where it is the most abundant glycoprotein 
(Haeryfar and Hoskin, 2004). As the latter term indicates, Thy-1 is heavily glycosylated with a 
carbohydrate content of up to 30% of its molecular mass in mice (Pont, 1987). The GPI anchor of the 
protein has been reported to contain alkylacylglycerol in its lipid moiety in rat brain (Homans et al., 
1988).
In mice, important immunological functions are attributed to Thy-1; upon formation of the
immunological synapse it can, by binding to a ligand on the surface of an antigen-presenting cell 
(APC), provide a costimulatory signal for T cell activation in the presence of a T cell-receptor 
(TCR)/MHC complex. Alternatively, in the absence of TCR, Thy-1 can itself induce T cell activation, 
even though these activated T cells do not exhibit any cytotoxic effector function (Haeryfar and 
Hoskin, 2004). In humans, Thy-1 is involved in widespread non-immunological processes like neurite 
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outgrowth, apoptotic signaling, cell adhesion and migration, tumor suppression and fibroblast 
proliferation. From a clinical point of view, the manifold regulatory and signaling functions of Thy-1 
render it an interesting molecule in disease-related pathways as for example wound healing, cancer 
metastasis or nerve regeneration (Rege and Hagood, 2006). 
1.4 Membrane Rafts 
1.4.1 General Background
Cellular membranes are generally known to form liquid-disordered bilayers, in which proteins and 
lipids are able to move freely and lipids mainly serve as solvent for membrane proteins (Singer and 
Nicolson, 1972). However, already more than ten years ago, the existence of more ordered, tightly 
packed and highly dynamic membrane assemblies of specific lipid composition was described 
(Simons and Ikonen, 1997). The presence of these domains, which were originally named “lipid 
rafts”, has been questioned for a long time (Munro, 2003), but now strong support has emerged for 
the concept and the existence of “membrane rafts” – as they are termed now – is generally 
accepted. Many attempts had been made to characterize and define membrane rafts, until, in 2006,
the following definition was agreed upon by the experts in the field: “Membrane rafts are small (10-
200 nm), heterogeneous, highly dynamic, sterol- and sphingolipid-enriched domains that
compartmentalize cellular processes. Small rafts can sometimes be stabilized to form larger 
platforms through protein-protein and protein-lipid interactions.” (Pike, 2006)
Figure 6: Model of the ordered structure of a membrane raft. GPL, glycerophospholipid; GSL, 
glycosphingolipid; SM, sphingomyelin; TM, transmembrane (adapted from: Lingwood and 
Simons, 2010) (Lingw ood a nd Simons, 2010)
As already indicated by the definition, membrane rafts exhibit a lipid and protein composition that 
distinguishes them from the liquid-disordered phase. Regarding lipids, the outer raft leaflet is mainly 
made up of sphingolipids and cholesterol, while the cytoplasmic leaflet contains mostly cholesterol 
and phospholipids (see Figure 6). In addition, also arachidonic acid and plasmenylethanolamine (see 
chapter 1.2) are enriched in membrane rafts isolated from human epidermal carcinoma cells (Pike et 
al., 2002). Generally, saturation level and chain length in lipid molecules are said to be higher in rafts 
compared with non-raft membranes, which accounts for the tight packing of the domains (Brown 
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and London, 1998). Similar to lipids, proteins are not equally distributed in the plasma membrane, 
either. Although some membrane spanning proteins, which are preferentially targeted to membrane 
rafts, have been identified – as for example members of the connexin family (Schubert et al., 2002) –, 
the hypothesis has arisen that mainly proteins with specific lipid modifications associate with rafts
(Levental et al., 2010). Among these molecules, GPI-anchored proteins (see chapter 1.3) hold a 
dominant position; the GPI anchor is presumed to constitute a sorting determinant already in the 
Golgi network (Brown and Rose, 1992). The length of the anchor has been shown to be critical for 
protein association with membrane rafts (Benting et al., 1999). Additional lipid modifications 
conferring raft preference to proteins include N-terminal myristoylation, cysteine acylations, 
isoprenylations and C-terminal sterol moieties (Levental et al., 2010).
Generally, membrane rafts are thought to compartmentalize biological processes at the plasma 
membrane (and possibly also at other cellular membranes). More precisely, important cellular 
activities are mediated by these domains such as signal transduction, membrane trafficking and 
protein sorting (Jacobson et al., 2007; Mayor and Rao, 2004). From a disease-relevant point of view, 
rafts serve as platforms that enable virus entry, assembly and budding (Chazal and Gerlier, 2003).
One reason, why the existence of membrane rafts was denied by many researchers for a long time, is 
the fact that they cannot be visualized by classical microscopy techniques. Due to their small size and 
their high turnover rate, advances have to be made to enable the examination of rafts with 
microscopic tools (Jacobson et al., 2007). However, other concepts and methods, one of which is 
introduced in the following chapter, have been developed to study raft biochemistry and functioning.
1.4.2 Detergent-Resistant Membranes (DRMs)
A key feature of membrane rafts is their detergent insolubility, which is a consequence of the 
interactions of saturated acyl chains (Schroeder et al., 1994). Upon exposure to Triton X-100 at 4 °C,
rafts do not solubilize and float to a characteristic density following equilibrium density gradient 
centrifugation (see also Figure 7) (Lingwood and Simons, 2007). According to the biological question 
to be answered, variable detergents with different solubilization properties are used (Schuck et al., 
2003). Although the isolation of detergent-resistant membranes (DRMs) is still the method of choice 
for determining affinity of lipids or proteins for membrane rafts, concerns have emerged about the 
artifacts produced by this method: First of all, DRM isolation is usually done at 4 °C, which might 
provoke lipid-protein associations that do not take place in vivo at growth temperature. Additionally, 
detergent treatment itself could induce – to a certain extent – membrane rearrangement or 
solubilize lipids that are known parts of membrane rafts (Quinn, 2010).
In spite of these drawbacks, DRM isolation is a widely accepted tool to study raft biology. Detergent-
free raft isolation procedures have been proposed (Shah and Sehgal, 2007; Smart et al., 1995), but 
never became the method of choice for most research questions. Furthermore, many of the major 
breakthroughs in the raft field originated from observations of changes in DRM association
(Lingwood and Simons, 2007). However, one should always keep in mind that DRMs cannot be 
equated with membrane rafts and results of DRM isolation experiments have to be interpreted with 
caution, although important hints can be gained by these efforts.
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1.5 Aims of the Study
As can be deduced from the introduction of this work, ether lipids constitute an essential part of 
mammalian cells. Many functions have been assigned to them, but still the involvement of these 
phospholipids in various cellular processes has to be elucidated. Additionally, lack of ether lipids 
causes the severe human disease RCDP, for which – at the moment – there is no cure. Accordingly, 
the main focus of this thesis was on ether lipid functions in mammalian, more precisely, in murine 
and human, tissue.
Depletion of plasmalogens constitutes a major problem for mammalian cells. Therefore, my thesis 
should clarify how cells react to such conditions and how they can compensate for the loss of these 
lipids. Another major goal was the evaluation of substances proposed for treatment of RCDP in cell 
culture and the response of plasmalogen-deficient cells to these compounds.
Ether lipids form important constituents of cellular membranes, especially of small subdomains 
called membrane rafts (Pike et al., 2002). The latter should be hit by ether lipid deficiency from two 
different sides: Firstly, membrane rafts contain high amounts of plasmalogens, the major class of 
ether lipids; and secondly, GPI-anchored proteins, a main protein species in rafts, cannot incorporate 
alkylacylglycerol into their lipid moiety under conditions of ether lipid deficiency. Therefore, my 
thesis was intended to shed light on the consequences of ether lipid absence for rafts and GPI-
anchored proteins. Furthermore, the role and importance of ether lipids in cellular membranes 
should be elucidated.  
Finally, RCDP patients as well as ether lipid-deficient mice exhibit severe motor deficiency, the origin 
of which is not clearly defined. With the help of the DAPAT ko mouse, a part of my diploma thesis 
was designed to study whether a defect in neuromuscular junction formation could account for the 
observed motor symptoms. 
Summarized, the present study was conceptualized to expand the current understanding of the 
functions and the role of ether lipids in mammals, eventually aiming at clarifying the molecular basis 
of the symptoms seen in RCDP and on possible treatment strategies for this disease. 
25
CHAPTER 2
2MATERIALS AND METHODS
2.1 Materials
2.1.1 Chemicals
Standard chemicals were purchased from Merck or Sigma-Aldrich.
Acrylamide 4X, Gerbu Biochemicals
Ammonium persulfate, Merck
DL-Batyl alcohol (99%), Sigma-Aldrich
Bisacrylamide 4k, Gerbu Biochemicals
Bovine serum albumin (BSA), Sigma-Aldrich
1-O-Hexadecyl-sn-glycerol (1-O-Palmityl-sn-glycerol), Alexis
1-O-Hexadecyl-2-hydroxy-sn-glycero-3-phosphate (ammonium salt), Avanti Polar Lipids Inc.
EDTA (ethylene diamine tetraacetic acid) disodium salt dihydrate, AppliChem
EGTA (ethylene glycol tetraacetic acid), Sigma-Aldrich
Ethidium bromide, Bio-Rad
5-Fluoro-2’-deoxyuridine, Sigma-Aldrich
Formaldehyde 37%, Merck
Gelatin from porcine skin type A, Sigma-Aldrich
Imidazole, Sigma-Aldrich
?-Mercaptoethanol, AppliChem
Mowiol, Carl Roth
NP-40, Calbiochem
Paraformaldehyde, Merck
Ponceau S, Fluka
Sodium deoxycholate, Merck
Sodium dodecyl sulfate (SDS), Sigma-Aldrich
Sucrose, Sigma-Aldrich
N,N,N’,N’-Tetramethylethylenediamine (TEMED), Merck
Tris(hydroxymethyl)-aminomethane (Tris), Merck 
Triton® X-100, Promega
Tween® 20, Merck
Urea, AppliChem
Uridine, Sigma-Aldrich
2.1.2 Enzymes, Kits and Special Materials
Amersham Hyperfilm™ ECL, GE Healthcare
cOmplete Protease Inhibitor Cocktail Tablets, Roche
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Deoxyribonuclease II (DNAse II) from bovine spleen, Sigma-Aldrich
dNTPs (deoxynucleotide triphosphates), Peqlab
DirectPCR® Lysis Reagent (Tail), Peqlab
GoTaq® DNA Polymerase and Buffer, Promega
Immobilon™ Western Chemiluminescent HRP Substrate, Millipore
Kodak® GBX Fixer/Replenisher, Sigma-Aldrich
Kodak® GBX Developer/Replenisher, Sigma-Aldrich
Oligonucleotides, custom-made by Eurofins MWG Operon
PageRuler™ Prestained Protein Ladder, Fermentas
Protein Assay, Bio-Rad
Proteinase K, Peqlab
Protran® Nitrocellulose Transfer Membrane, Whatman
Recombinant Murine Interferon-gamma, PeproTech
Trypsin from bovine pancreas, Sigma-Aldrich
Whatman® Filter Papers, Whatman
2.1.3 Expendables
Corning® Bottle-Top Vacuum Filters, Sigma-Aldrich
Cover Slips 21x26 mm, Carl Roth
Falcon™ Cell Strainers, BD Biosciences
Injekt®-F Single Use Syringes, Braun
Microscope Slides 76x26 mm, Carl Roth
PrecisionGlide® Sterile Needles, BD Biosciences
Serological Pipettes, Sarstedt
Sterican® Hypodermic Needles, Braun 
Tissue Culture Cell Scrapers, Sarstedt
Ultra-Clear™ Centrifuge Tubes, Beckman
2.1.4 Antibodies and Probes
Primary: 
Monoclonal mouse anti-actin (clone C4), Chemicon®, Millipore
?-Bungarotoxin-Alexa Fluor® 594 conjugate, Molecular Probes™, Invitrogen
Polyclonal rabbit anti-CD55, GeneTex
Polyclonal rabbit anti-connexin 43/GJA1, Abcam
Monoclonal mouse anti-flotillin-1, BD Transduction Laboratories™, BD Biosciences
Polyclonal rabbit anti-Thy-1 (CD90), Epitomics
Monoclonal rat anti-Thy-1.2 (CD90) (clone 30-H12), Leinco Technologies
Monoclonal mouse anti-transferrin receptor (clone H68.4), Zymed®, Invitrogen
Secondary:
Goat anti-rabbit IgG (H+L) HRP (horseradish peroxidase) conjugate, Bio-Rad
Goat anti-mouse immunoglobulins (polyclonal) HRP conjugate, Dako
Goat anti-rat IgG (H+L) Cy3 conjugate, Amersham®, GE Healthcare
Donkey anti-rabbit IgG (H+L) Cy3 conjugate, Jackson ImmunoResearch
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2.1.5 Laboratory Equipment
Casy®1 Cell Counter, Schärfe System
Cell Culture Incubators, Heraeus
Centrifuge 5415D, Eppendorf
DM IRB Inverted Microscope, Leica
Electrophoresis Power Supply E425, Consort
Fluovert Microscope, Leitz
Gel Doc™ 2000, Bio-Rad 
GeneAmp 2400 PCR System, Perkin Elmer
Gene Power Supply GPS 200/400, Pharmacia 
IX71 Inverse Fluorescence Microscope, Olympus
MAC-5000 Controller System, Visitron Systems
Megafuge 1.0, Heraeus
Mini-PROTEAN® 3 Electrophoresis System, Bio-Rad
MyCycler™ Thermal Cycler, Bio-Rad
Optima™ LE-80k Ultracentrifuge, Beckman
PHM92 Lab pH Meter, Radiometer Analytical
PowerPac™ 3000 Power Supply, Bio-Rad
PowerPac™ HC Power Supply, Bio-Rad
PowerShot SX20 IS Digital Camera, Canon
Quattro II Triple Quadrupole Mass Spectrometer, Micromass
Refrigerated Centrifuge 4K15, Sigma
Rota-Rod Treadmill for Mice No. 7650, Ugo Basile
Spot Xplorer™ Digital Camera, Diagnostic Instruments
Thermomixer comfort, Eppendorf
Trans-Blot® Semi-dry Electrophoretic Transfer Cell, Bio-Rad
UV-Visible Spectrophotometer U-2001, Hitachi
VBH Compact C2 Cell Culture Lamina Hood, Steril Manufacturing Division
Vortex-Genie™, Scientific Industries
Water Bath No. 1003, GFL
XM10 Digital Camera, Olympus
2.1.6 Software
ACD/ChemSketch 12.0, ACDLabs
Acrobat 9 Professional, Adobe
Cell^M Imaging Software, Olympus
CorelDraw Graphics Suite X4, Corel
EndNote X3, Thomson Reuters
MetaMorph Microscopy Automation & Image Analysis Software 7.0, Molecular Devices
Office 2007, Microsoft
Photoshop CS4, Adobe
PASW Statistics 17, SPSS Inc.
Quantity One 4.2.3, Bio-Rad
SigmaPlot 11.0, Systat Software
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2.1.7 Cell Culture
DMEM (Dulbecco’s Modified Eagle Medium) (with 4,5 g/l glucose; without L-glutamine), 
BioWhittaker®, Lonza
Fetal Bovine Serum (FBS), PAA
Fungizone, Gibco®, Invitrogen
L-Glutamine (in NaCl solution), BioWhittaker®, Lonza
Horse Serum (HS), PAA
PenStrep (10 000 U/ml penicillin, 10 000 µg/ml streptomycin), Gibco®, Invitrogen
Phosphate Buffered Saline (PBS), BioWhittaker®, Lonza
RPMI 1640 (without L-glutamine), BioWhittaker®, Lonza
Trypsin EDTA, BioWhittaker®, Lonza
CELLSTAR® Cell Culture Dishes and Flasks, Greiner Bio-One
2.1.8 Cells
Human RCDP fibroblast cell lines were obtained from Dr. Nancy Braverman (McGill University, 
Montreal) in the course of a collaboration. Control fibroblast lines were already available in the lab. 
DAPAT knockout and corresponding wild type mouse fibroblast cell lines were received from Prof. Dr. 
Wilhelm Just (Heidelberg University Biochemistry Center).
Human fibroblast cell lines were cultivated in RPMI 1640 medium supplemented with 10% FBS (heat 
inactivated at 56 °C for 30 minutes), 1% PenStrep (50 U/ml penicillin, 100 µg/ml streptomycin), 2 mM
L-glutamine and 0.5% fungizone. Mouse fibroblast cell lines were grown in DMEM medium with the 
same supplements. For splitting, cells were detached by incubation with 0.25% trypsin at 25-37 °C for 
5-30 minutes and distributed to several dishes. Trypsin was inactivated by normal FBS 
concentrations. Splitting ratios were kept between 1:2 and 1:5. All cell lines were cultivated at 37 °C 
and a CO2 concentration of 5%. Measurements were exclusively carried out between passages 5 and 
30. 
For plasmalogen precursor treatment studies, fibroblasts were supplemented with 20 µM 
hexadecylglycerol or batyl alcohol (each dissolved in ethanol; final ethanol concentration: 1%) for 
three subsequent days with medium changes every 24 hours. Thereafter, the cells were harvested 
and phospholipids determined as described below.
All studies involving human patient fibroblasts were approved without restrictions by the Ethical 
Review Board at the Medical University of Vienna (application number: 729/2010). 
2.1.9 Mice
DAPAT knockout mice (outbred C57BL/6 x CD1) were originally received from the laboratory of Prof. 
Dr. Wilhelm Just (Heidelberg University Biochemistry Center), where these mice have been 
generated (Rodemer et al., 2003), and maintained at the local animal housing facility of the Medical 
University of Vienna. Issues concerning the regulations for the use of genetically modified animals 
were resolved and experiments involving these animals approved (BMWF-5.011/0003-II/10b/2009). 
Mice were fed standard mouse chow with food and water ad libitum and were housed in a 
temperature- and humidity-controlled room with 12:12 hour light-dark cycle and a constant low level 
of acoustic background noise. 
Materials and Methods
29
All animals received humane care in compliance with the Principles of Laboratory Animal Care 
(National Society for Medical Research) and the Guide for the Care and Use of Laboratory Animals, 
prepared by the National Academy of Sciences and published by the National Institutes of Health 
(NIH Publication No. 86-23, revised 1985). 
2.2 Methods
2.2.1 Preparation of Cellular Membranes
The desired number of cells (5-20 dishes of 10 cm diameter) was grown to confluency, washed twice
with sterile phosphate buffered saline (PBS) and scraped into homogenization buffer with 1x 
protease inhibitor. Cells were homogenized by 2 passages through a 23 G (gauge), and 3 passages 
each through a 25 G and a 27 G needle. Subsequently, nuclei and unbroken cells were pelleted by 
centrifugation at 5,700xg, 4 °C for 15 minutes and the postnuclear supernatant was transferred to an 
ultracentrifuge tube (Ultra-Clear Tube 14x95 mm). Ultracentrifugation was carried out at 100,000xg 
(23,800 rpm), 4 °C for 30 minutes in an SW 40 Ti rotor (Beckman). The resulting membrane pellet was 
resuspended in 10 µl/106 cells RIPA buffer with 1x protease inhibitor and stored at -20 °C or -80 °C. 
Homogenization buffer: 250 mM sucrose, 3 mM imidazole, 1 mM EDTA; pH 7.4
25x protease inhibitor: 1 cOmplete Protease Inhibitor Cocktail Tablet in 2 ml dH2O6
RIPA buffer: 50 mM Tris-Cl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% NP-40 (vol/vol), 1% 
sodium deoxycholate (wt/vol), 0.1% sodium dodecyl sulfate (SDS) (wt/vol)
2.2.2 Preparation of Total Protein Extracts
The desired number of cells (∼1 confluent 10 cm dish) was washed twice with sterile PBS and scraped 
into 1 ml/106 cells ice-cold RIPA buffer with 1x protease inhibitor. Cells were homogenized by 3 
passages through a 27 G needle on ice and the homogenate was centrifuged at 16,100xg, 4 °C for 20 
minutes in a tabletop centrifuge. The resulting supernatant was stored at -20 °C.
RIPA buffer: 50 mM Tris-Cl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% NP-40 (vol/vol), 1% 
sodium deoxycholate (wt/vol), 0.1% SDS (wt/vol)
25x protease inhibitor: 1 cOmplete Protease Inhibitor Cocktail Tablet in 2 ml dH2O
2.2.3 Isolation of Detergent-Resistant Membranes (DRMs)
Preparation of DRMs was basically performed as described by Lingwood & Simons (Lingwood and 
Simons, 2007). The whole isolation procedure was carried out on ice (harvesting of cells) or at 4 °C in 
a refrigerated room (residual steps). 
The desired number of cells (∼20 dishes of 10 cm diameter) was grown to confluency, washed once 
with sterile PBS and once with TNE and scraped into TNE buffer. Cells were pelleted by centrifugation 
at 400xg, 4 °C for 5 minutes and the pellet resuspended in 550 µl TNE supplemented with 1x 
protease inhibitor. Subsequently, the cells were homogenized by 25 passages through a 25 G needle. 
To 500 µl of the homogenate, 500 µl of TNE/protease inihibitor + 2% Triton X-100 (vol/vol) were 
6 dH2O refers to deionized water.
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added and the mixture was incubated on ice for 30 minutes. The sample was adjusted to 40% 
sucrose/TNE (wt/wt) by addition of 2 ml 56% sucrose/TNE (wt/wt), transferred to the bottom of an 
ultracentrifuge tube (Ultra-Clear Tube 14x95 mm) and overlaid with 8.5 ml 35% sucrose/TNE (wt/wt) 
and 0.5 ml 5% sucrose/TNE (wt/wt). Ultracentrifugation was carried out at 271,000xg (39,000 rpm), 
4 °C for 18 hours in an SW 40 Ti rotor (Beckman). One ml-fractions were collected from the top and 
analyzed by western blotting for presence of raft markers or stored at -20 °C. A scheme of the 
procedure is presented in Figure 7.
TNE buffer: 150 mM NaCl, 2 mM EDTA, 50 mM Tris-Cl (pH 7.4)
25x protease inhibitor: 1 cOmplete Protease Inhibitor Cocktail Tablet in 2 ml dH2O
Figure 7: Principle of DRM isolation. After Triton lysis, DRMs float to the lightest fractions of a 
sucrose gradient during centrifugation and can be separated from residual cellular material.
2.2.4 Determination of Protein Concentration
Protein samples were diluted to 100 µl with dH2O and subsequently mixed with 1 ml pre-diluted 
Protein Assay reagent (final concentration 1:5). After 10 minutes incubation for dye color 
development, absorption at 595 nm was measured in a spectrophotometer. Standard curves were 
established by using BSA samples with protein concentrations ranging from 0 to 10 µg. 
2.2.5 SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE)
Protein samples were diluted to an appropriate volume with dH2O and supplied with SDS sample 
buffer followed by heating at 85-99 °C (temperature according to protein of interest) for 10 minutes 
and centrifugation at 16,100xg, room temperature for 30 seconds to remove insoluble material. To 
enhance protein solubilization, urea was added to selected samples at a final concentration of 1 M
prior to heating. Samples were applied to SDS gels of either 0.75 mm or 1.5 mm thickness. 
Separation was done at a constant current of 30 mA (0.75 mm gels) or 50 mA (1.5 mm gels), for 1-2 
hours depending on sizes of the proteins to be detected (settings apply for two gels in one 
electrophoretic chamber of the Mini-PROTEAN® 3 system, Bio-Rad). 
Acrylamide working solution: 30% acrylamide (wt/vol) , 0.8% bisacrylamide (wt/vol)
Polyacrylamide separation gel (12%; amount of acrylamide can be adapted): 12% acrylamide, 20% 
1.5 M Tris-Cl (pH 8.8), 0.1% SDS, 0.15% TEMED, 0.5% APS; covered with a layer of isopropanol until 
polymerized
Polyacrylamide stacking gel: 4% acrylamide, 12.5% 1 M Tris-Cl (pH 6.8), 0.1% SDS, 0.15% TEMED, 
0.5% APS 
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4x SDS sample buffer: 250 mM Tris-Cl (pH 6.8), 8% SDS (wt/vol), 40% glycerin (vol/vol), 20% ?-
mercaptoethanol (vol/vol), 0.008% bromophenol blue (wt/vol)
SDS running buffer: 2.5 mM Tris, 25 mM glycine, 0.1% SDS (wt/vol)
2.2.6 Western Blot
After SDS-PAGE, the gels were washed with water and equilibrated in blotting buffer. Sandwiches for 
semi-dry blotting were prepared as follows (all materials were pre-wet in blotting buffer): 3 sheets of 
Whatman paper (thickness: 3 mm; size: 8.5x5.5 cm) were put at the bottom of the Trans Blot 
Electrophoretic Transfer Cell followed by a nitrocellulose membrane (0.2 µm mesh) of the same size
overlaid by the SDS gel. On top, 3 further sheets of Whatman paper were placed and residual buffer 
was removed. Settings for two blots (in one cell) were constant current of 260 mA with a maximum 
voltage of 25 V for 25-30 minutes (according to thickness of SDS gels and sizes of proteins to be 
detected). 
Membranes were rinsed with water and incubated with Ponceau staining solution for 5 minutes 
followed by another wash step with water in order to visualize protein transfer efficiency. Blocking 
was carried out with 4% non-fat dry milk (wt/vol in TBST) for 2x30 minutes at room temperature. In 
some cases, additional blocking with 3% BSA/TBST (wt/vol) for 1 hour was done. After thorough 
washing with TBST, membranes were exposed to primary antibodies (diluted in TBST) overnight at 
4 °C on a rocking platform. They were again washed with TBST and incubated with HRP-conjugated 
secondary antibodies (diluted in TBST) for 2 hours at room temperature, followed by washing in 
TBST. Signals were detected using the Immobilon Western HRP Substrate; Peroxide Solution and 
Luminol Reagent were mixed in a 1:1 ratio and the membrane incubated for 5 minutes under 
constant agitation. A photographic ECL film was applied for the desired time (according to strength of 
the signal) and then incubated in developing solution for 1 minute, followed by rinsing with H2O and 
incubation in fixing solution for 5 minutes. If desired, the membrane was stripped for 3x5 minutes
with stripping buffer, blocked as described and reprobed with additional antibodies.
Blotting buffer: 48 mM Tris, 39 mM glycine, 20% methanol (vol/vol), 0.0375% SDS (wt/vol)
TBST (Tris Buffered Saline/Tween): 25 mM Tris-Cl (pH 7.5), 150 mM NaCl, 0.05% Tween 20 (vol/vol)
Stripping buffer: 200 mM glycine, 500 mM NaCl; pH 2.5 (adjusted with HCl) 
Ponceau working solution: 0.1%  Ponceau S (wt/vol) in 5% (vol/vol) acetic acid
Developing working solution: 110 ml GBX developer/replenisher + 390 ml H2O 
Fixation working solution: 110 ml GBX fixer/replenisher + 390 ml H2O
Concentrations of antibodies used: Mouse anti-actin, 1:50,000 
Rabbit anti-CD55, 1:2,000
Rabbit anti-connexin 43, 1:32,000 
Mouse anti-flotillin-1, 1:1,000
Rabbit anti-Thy-1, 1:5,000
Mouse anti-transferrin receptor, 1:2,000
Goat anti-rabbit IgG-HRP, 1:40,000
Goat anti-mouse Ig-HRP, 1:40,000
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2.2.7 Immunofluorescence of Blood Samples
A drop of blood was taken from the tail tip of mice, streaked onto microscopy slides and air-dried. 
The slides were washed twice with PBS for 5 minutes, incubated in fixing solution at room 
temperature for 20 minutes, and again washed twice for 10 minutes. Samples were blocked with 
10% BSA (wt/vol in PBS) at 37 °C for 30 minutes followed by primary antibody (diluted in PBS + 1% 
BSA) incubation at 37 °C for 30 minutes. The slides were washed twice with PBS and exposed to a 
fluorescent-dye labeled secondary antibody (diluted in PBS + 1% BSA) at 37 °C for 30 minutes in the 
dark. After two washing steps with PBS, the slides were rinsed with dH2O and mounted with 5 µl 
geltol using a small cover slip. 
Fixing solution: 3% paraformaldehyde (wt/vol), 1% picric acid (vol/vol) in PBS 
PBS (Phosphate Buffered Saline): 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4; pH 7.4 
(adjusted with NaOH)
Geltol: 6% glycerin (vol/vol), 2.4% Mowiol (wt/vol), 24 mM Tris-Cl (pH 8.5) (after addition of Tris-Cl, 
the solution was stirred at 50° C for 10 minutes followed by centrifugation at 5,000xg for 15 minutes)
Concentrations of antibodies used: Rat anti-Thy-1.2, 1:200
Goat anti-rat IgG-Cy3, 1:100
2.2.8 Immunofluorescence of Cultured Cells
Cells were grown on uncoated cover slips to the desired density. They were rinsed with sterile PBS, 
fixed with 3.7% formaldehyde (wt/vol in PBS) for 15 minutes and washed three times with PBS. The 
cover slips were blocked for 90 minutes at room temperature and washed with PBS. Primary 
antibodies diluted in PBS + 10% FBS (vol/vol) were applied for 2 hours in a humidity chamber at room 
temperature. After washing, secondary antibodies (in 10% FBS/PBS) were added for 1 hour at room 
temperature in the dark, the cells washed with PBS and mounted on a microscopy slide using 7 µl 
geltol.
Blocking solution: 1% BSA (wt/vol), 10% FBS (vol/vol) in PBS
PBS (Phosphate Buffered Saline): 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4; pH 7.4 
(adjusted with NaOH)
Geltol: 6% glycerin (vol/vol), 2.4% Mowiol (wt/vol), 24 mM Tris-Cl (pH 8.5)
Concentrations of antibodies used: Rat anti-Thy-1.2, 1:250
Rabbit anti-Thy-1, 1:250
Donkey anti-rabbit IgG-Cy3, 1:400
Goat anti-rat IgG-Cy3, 1:100
2.2.9 Preparation and Cultivation of Primary Myoblasts
Isolation of myoblasts and acetylcholine receptor cluster analyses were carried out in cooperation 
with the group of Dr. Ruth Herbst (Center for Brain Research, Medical University of Vienna). 
Experiments were performed together with Mag. Susan Luiskandl. 
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Newborn mice (postnatal day 0 to postnatal day 2) from DAPAT (+/-) x DAPAT (+/-) matings were 
sacrificed by cervical dislocation and the tail tip dissected for determination of genotype. After 
washing with ethanol, limbs were removed, freed of skin and subsequently stored at 37 °C in an 
atmosphere of 6% CO2 overnight. After genotyping, for samples of interest, toes and large bones 
were removed and the residual tissue was placed in PBS/1% glucose. The tissue was broken into 
smaller pieces while getting rid of fat, bones, residual skin and tendons, and finally surgical scissors 
were used to generate pieces of ∼1 mm3. Muscle slurry was taken up in 1 ml PBS/1% glucose
(wt/vol), then supplemented with 125 µl 2% trypsin and 125 µl 0.1% DNase II, and the mixture
incubated at 37 °C/6% CO2 for 30 minutes. After addition of 5 ml growth medium, residual pieces of 
muscle were broken up with the help of a pipet and cells collected by centrifugation at 400xg. The 
supernatant was removed, 2 ml growth medium were added and the mixture was triturated with a 
glass pipet until no more tissue pieces were visible. The volume was adjusted to 4-5 ml with growth 
medium and the solution passed through a cell strainer (70 µm mesh). The resulting suspension was 
plated onto an uncoated 60 mm-petri dish and incubated at 37 °C/6% CO2 for 30 minutes to enable 
adherence of co-isolated fibroblasts. The petri dish was tilted and the supernatant containing 
myoblasts collected. Cells were counted and 5-8x105 cells each plated onto 35 mm-petri dishes 
coated with 0.2% gelatin followed by incubation at 37 °C/6% CO2 with medium changes every 1-2 
days.
Primary myoblast growth medium: DMEM + 10% FBS, 10% horse serum (HS), 1% PenStrep, 0.5% 
chicken embryo extract, 200 µl/100 ml interferon-gamma (100,000 units/µl)
2.2.10 Myotube Formation, Agrin Stimulation and Staining of Acetylcholine 
Receptor Clusters
Differentiation of confluent myoblasts was induced by a switch from growth to differentiation 
medium. During the differentiation process, medium was changed daily. Fluorodeoxyuridine (FUDR)
was added to the medium 24 hours after differentiation was initiated in order to inhibit myoblast 
and fibroblast proliferation. Cells were generally used for agrin stimulation on day 2-3 after start of 
differentiation, depending on the formation of prominent myotubes.
Stimulation with recombinant agrin was done for 11 hours and the cells were subsequently stained 
with bungarotoxin-Alexa Fluor 594 at 37 °C/6% CO2 for 1 hour. Myotubes were washed three times 
with PBS, fixed with 1% paraformaldehyde (wt/vol in PBS) for 10 minutes at room temperature, again 
washed three times and mounted under a cover slip with 8 µl Mowiol. The samples were kept in the 
dark at 4 °C until visualization by fluorescence microscopy.
Primary myoblast differentiation medium: DMEM + 10% FBS, 10% HS, 1% PenStrep
100x FUDR stock: 0.61 mM FUDR, 1.47 mM uridine in PBS 
?-Bungarotoxin-Alexa Fluor 594: 1:5,000 in PBS
2.2.11 Isolation of DNA from Cultured Cells
DNA was isolated from cultured cells by using the DNeasy® Blood & Tissue Kit (Qiagen), according to 
the manufacturer’s manual with an average cell number of ∼5x106. DNA was generally eluted in a 
final volume of 200 µl elution buffer, of which 1 µl was included in subsequent PCR reactions. 
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2.2.12 Agarose Gel Electrophoresis
The desired amount of agarose (e.g. 1 g/100 ml buffer for a 1% gel) was taken up in TAE buffer and 
boiled for 3 minutes until agarose was fully dissolved. Ethidium bromide (final concentration 0.5 
µg/ml) was added after a 10-minute cooling period, the gel poured into the corresponding trays and 
supplied with appropriate combs. After solidification, gel trays were placed in electrophoresis 
chambers filled with TAE buffer, samples applied and the gel was run at constant 90 V for about 1 
hour. DNA was visualized using Gel Doc 2000 and the corresponding Gel Doc software (Bio-Rad). 
TAE (Tris-Acetate-EDTA) buffer: 40 mM Tris-acetate, 1 mM EDTA; pH 8.0
2.2.13 Murine DAPAT Genotyping
DNA was obtained either from cultured cells using the DNeasy® Blood&Tissue Kit as described above 
or from mouse tails. Briefly, mouse tail tips (<5 mm) of 18-20 days-old-mice were resected and lysed
in 150 µl Tail Lysis Reagent + 2 µl Proteinase K (final concentration: ∼0.3 µg/µl) at 55 °C for 4 hours. 
The enzyme was inactivated by incubation at 85 °C for 45 minutes. Subsequently, the sample was 
centrifuged at 16,100xg, room temperature for 30 seconds and the supernatant stored at 4 °C until 
PCR analysis. 
The PCR primers used were OLI 1626 (5’-CGATACCTACTTTGTCCCAATTAGC-3’), OLI 1627 (5’-
GCTGGTCTCAAACAGCTACGTAGCTGA-3’) and OLI 1628 (5’-CGCATCGCCTTCTATCGCCTTCTTG-3’) with 
OLI 1626 and OLI 1627 amplifying exon 7 of the wild type DAPAT gene, and OLI 1628 and OLI 1627 
amplifying the neomycin cassette-DAPAT junction of the DAPAT knockout allele (Rodemer et al., 
2003). 
PCR reactions consisted of 4 µl 10x GoTaq Buffer, 0.4 µl dNTPs (10 mM each), 1 µl of each 
oligonucleotide (10 pmol/µl), 11.5 µl dH2O, 0.1 µl GoTaq Polymerase and 1 µl DNA (final volume: 20 
µl).  
After 4 minutes denaturation at 94 °C, PCR was performed for 30 cycles of 94 °C for 20 seconds 
followed by 60 °C for 20 seconds and 72 °C for 50 seconds. Final extension was done at 72 °C for 7 
minutes, before cooling to 10 °C holding temperature. 
The resulting fragments were ∼650 bp in length for the wild type allele and ∼860 bp for the knockout 
allele. 
2.2.14 Murine Thy-1 Genotyping
DNA was obtained as described above. Primers used for Thy-1 genotyping experiments were OLI 
1733 (5’-TGGGATTCTCGCCCGAGAGTC-3’), OLI 1734 (5’-TGGGATTCTCGCCCGAGAGTC-3’) and OLI 1735 
(5’-GCCTGACAGCCTGCCTGGTGA-3’) with OLI 1733 and OLI 1735 amplifying the Thy-1.1 allele, and 
OLI 1734 and OLI 1735 amplifying the Thy-1.2 allele. For every sample, a separate reaction was set up
for each primer combination. Reagent concentrations were as described for DAPAT genotyping. 
PCR program: initial denaturation at 94 °C for 4 minutes followed by 30 cycles of 94 °C for 20 
seconds, 57 °C for 20 seconds and 72 °C for 50 seconds. Final extension was done at 72 °C for 7 
minutes, before cooling to 10 °C holding temperature. 
The resulting PCR products were ∼270 bp in length for both assays. 
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2.2.15 Measurement of Cellular Phospholipids
Determination of phospholipids in fibroblast lines was carried out in cooperation with the group of 
Prof. Dr. Felix Wieland (Heidelberg University Biochemistry Center); lipidomic analyses were 
performed by Dr. Alexander Brodde and Dr. Britta Brügger.
An appropriate number of cells (1-2 nearly confluent 10 cm dishes) was washed with sterile PBS and 
dH2O and subsequently scraped into 1 ml of dH2O. Extracts were obtained by homogenization using 
23 G (2 passages), 25 G (2 passages) and 27 G (3 passages) needles. Cellular extracts were shock-
frozen in liquid nitrogen and stored at -80 °C until mass spectrometry.
Mass spectrometric analyses were done on a triple quadrupole instrument equipped with a nano-
electrospray ionization (ESI) source. The source temperature was set to 30 °C and a capillary voltage 
of ±600-900 V was applied, depending on the ion mode. Argon was used as collision gas at a nominal 
pressure of 2.5x10-3 mbar. Lipid standards dissolved in chloroform:methanol (1:2 vol/vol) were added 
to the extraction solvent prior to lipid extraction, which was performed according to the method of 
Bligh and Dyer (Bligh and Dyer, 1959). Dried lipids were dissolved in methanol containing 10 mM 
ammonium acetate. Quantification of phosphatidylcholine (PC) and sphingomyelin (SM) was 
performed as described (Brugger et al., 2004). Quantitation of phosphatidylethanolamine (PE) and 
phosphatidylserine (PS) was performed by neutral loss scanning, selecting for a neutral loss of 141 Da 
or 185 Da (positive ion mode), respectively, with a collision energy of 20 eV (Brodde, 2009; Zemski 
Berry and Murphy, 2004). Plasmenylethanolamine (PL-PE) quantitation was performed by precursor 
ion scanning for fragment ions 364 Da, 390 Da and 392 Da (positive ion mode, collision energy of 18-
20 eV). Unsaturated PE and PS standards were synthesized and purified via HPLC (Koivusalo et al., 
2001) and PL-PE standards were synthesized as described (Brodde, 2009; Paltauf and Hermetter, 
1994). Quantitative analyses were performed as described (Brugger et al., 1997; Brugger et al., 2000). 
Phosphate determination was done according to Rouser (Rouser et al., 1970). 
2.2.16 Behavioral Studies
All mice exposed to behavioral testing were males. With regard to mice being nocturnal animals, all 
trials were conducted after 6 p.m. under suitable dim light conditions. 
Rotarod
Rotarod experiments were basically carried out as already described (Dumser et al., 2007). Briefly, 5 
mice were placed on separate lanes on the rotating cylinder of an accelerating Rotarod apparatus. 30 
to 60 seconds were allowed for familiarization. Subsequently, the accelerating mode was switched 
on. In a five minute period, the apparatus accelerated from 4 to 40 rpm and was left running at 
constant 40 rpm until a maximum time of 500 seconds from the start. Time from start to fall (in 
seconds) was automatically recorded. Two rotations of mice holding on to the cylinder were assessed 
as a fall. 
A 3 day training/test scheme was applied: Mice were trained three times on two consecutive days 
followed by performance of the test in four consecutive trials on the third day. Suitable resting 
periods were allowed between the trials. Mean values of the best three trials on the test day were 
calculated for every mouse und used for statistical analysis. 
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Balance Beam
Mice were placed on the balance beam, a 60 cm long wooden bar located 23 cm above the ground. A 
horizontal midline was drawn on the beam to check for murine limb coordination deficits. Mice were 
allowed to explore their surroundings and were then relocated to one end of the bar. Movement 
across the beam was encouraged; a young healthy mouse typically runs swiftly across with all four 
paws at the top of the beam. Performances were evaluated according to a scoring system (see
chapter 3.6.1) by two independent supervisors. 
Three consecutive trials interrupted by suitable resting periods were carried out for each mouse. The 
best evaluation result (usually reached in the third trial) was chosen for statistical analysis.  
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CHAPTER 3
3RESULTS
3.1 Phospholipid Profiles Reveal Compensatory Alterations in Ether 
Lipid-Deficient Human Cell Lines
The role of ether lipids in the living organism can be studied best in models, in which biosynthesis of 
these molecules is defect. In humans, ether lipid deficiency leading to RCDP is evoked by mutations
in the peroxisomal enzymes DAPAT and AGPS as well as the PEX7 receptor responsible for the import 
of AGPS (see chapter 1.2.1). Therefore, primary fibroblast cell lines derived from skin biopsies of 
RCDP patients were obtained. All three types of the disease in their mild and severe forms were 
selected for this study. An overview of the mutations in the genes that are affected in each fibroblast 
line is given in Table 1.
Cell Line Affected Gene Mutations Patient Phenotype
RCDP 1-1 PEX7 H285R/L292X mild
RCDP 1-2 PEX7 H39P/W206X severe
RCDP 1-3 PEX7 L292X/L292X severe
RCDP 2-1 GNPAT7 c.c. 1937+5G>A mild
RCDP 2-2 GNPAT c. 1428delC/1428delC severe
RCDP 3-1 AGPS E471K/E471K mild
RCDP 3-2 AGPS T568M/T568M severe
Table 1: Primary fibroblasts derived from RCDP patients and their corresponding mutations. Amino 
acid exchanges are indicated in the one-letter code. X designates the presence of a premature stop 
codon.
Prior to the examination of ether lipid-deficient cell lines, the phospholipid profile was studied in 
three human control fibroblast lines (derived from healthy patients). As depicted in Figure 8, 
phospholipids were divided into five different main classes, namely phosphatidylcholine (PC), 
phosphatidylethanolamine (PE), phosphatidylserine (PS), sphingomyelin (SM) and 
plasmenylethanolamine (PL-PE). PC was found to be the major phospholipid species accounting for 
about 40%8 of the total phospholipid mass. The remaining phospholipid amount was distributed 
rather equally among the other four species, each making up approximately 10-15% of all 
phospholipids. Quantification of plasmenylethanolamines showed an average relative amount of 
about 12% in control cells.
7 GNPAT encodes the DAPAT protein (see chapter 1.2).
8 All percentages presented in chapter 3.1 and 3.2 are mole%.
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Figure 8: Phospholipid profile of human control fibroblasts. Depicted values were calculated as 
means of three different cell lines each measured in biological triplicates. Error bars indicate 
standard deviations. P-, phosphatidyl-; PL-PE, plasmenylethanolamine
3.1.1 Plasmalogen Content of Human Cell Lines Only Partially Reflects 
Clinical Severity
In RCDP patients, the clinical phenotype has been observed to correlate with the amount of 
plasmalogens synthesized (Braverman et al., 2002). In order to determine, whether this holds true in 
cultured fibroblasts derived from patients, quantification of all ethanolamine plasmalogen species 
was performed by lipidomic analysis of cell lysates using nano-ESI mass spectrometry (in cooperation 
with Dr. Alexander Brodde and Dr. Britta Brügger). Three fibroblast lines originating from healthy 
individuals were chosen as control group.
In the latter, ethanolamine plasmalogens were found to account for 10-15% (see also Figure 8) of all 
measured phospholipids. Analysis of plasmalogen levels revealed a significant reduction of about 
40% in fibroblasts of patients with a mild disease course when compared with control cells (Figure 9). 
In addition, plasmalogen amounts in cells derived from severely impaired patients were significantly 
lower than those in the “mild course” group and reached levels of about 15-40% of the control 
values. However, levels in fibroblasts from patients with severe phenotype turned out to be 
heterogeneous with some cells behaving rather like cells from the “mild course” (RCDP 1-3, RCDP 3-
2) group and others exhibiting very low plasmalogen amounts (RCDP 1-2, RCDP 2-2). 
Morphologically, there was no difference between the different cell lines of the “severe course” 
group with the exception of a slower growth rate of RCDP 1-3 and RCDP 3-2 compared with all other 
patient and control cell lines. Thus, owing to the observed heterogeneity, only fibroblast lines RCDP 
1-2 and RCDP 2-2 should be considered as severely affected by ether lipid deficiency. 
Taken together, though, these results confirm the observation of a direct correlation between the 
residual levels of plasmalogen and disease severity in RCDP patients.
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Figure 9: Ethanolamine plasmalogen levels in control and RCDP patient fibroblasts. Significant 
reductions can be observed in cells of patients with mild and severe disease courses, respectively, 
as compared to control cells. Error bars indicate standard deviations (n=3 for each individual cell
line9). *** P<0.001 compared with “healthy” group; * P<0.05 compared with “healthy” group; 
+ P<0.05 compared with “mild course” group. Statistical analysis was carried out using one-way 
ANOVA followed by Bonferroni’s multiple comparison test. 
3.1.2 The Distribution of Fatty Alcohols at the sn-1 Position of Plasmalogens 
Is Altered in Fibroblast Cultures Deficient in Ether Lipid Synthesis
In plasmalogens, the sn-1 position is occupied by a saturated or monounsaturated (only in case of 
C18) alkyl chain with a length of 16 or 18 carbon atoms. To judge, which of these species are 
dominant in human fibroblasts and whether the alkyl chain distribution is changed upon reduction of 
plasmalogens, the proportion of each species was determined by mass spectrometry.
In control fibroblasts, C16:0 was the most frequent species at the sn-1 position accounting for more 
than 40% of all ethanolamine plasmalogens (see Figure 10). Concerning C18 chains, the saturated 
form seemed to be more abundant than the monounsaturated form. However, it is of notice that this 
distribution was quite heterogeneous within the three different control lines, e.g. with C18:0 
accounting for ∼40% of PL-PEs in one control line as opposed to less than 30% in another. The 
distribution in fibroblasts mildly affected by ether lipid deficiency mainly reflected that of the control 
group, although a slight tendency to replace C16:0 with C18:0 could be observed. In cells derived 
from patients suffering from severe RCDP, changes in the fatty alcohol profile of the sn-1 position 
were discovered: The amounts of C18:0 were lowered in all respective cell lines, whereas in turn the 
levels of the other two species were slightly increased. Interestingly, these differences between 
fibroblasts of severely affected patients and controls were even more pronounced, when only the 
more slowly growing cell lines (RCDP 1-3 and RCDP 3-2) were considered. Yet, these observations 
9 Each value of a given cell line represents an independent, separate culture, from which phospholipids were 
extracted for analysis.
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have to be treated with caution due to the heterogeneity at the sn-1 position in the control group. 
Figure 10B shows an overview of the alkyl chain composition at sn-1 in the three different groups. 
Figure 10: Fatty alcohol distribution at the sn-1 position of ethanolamine plasmalogens. (A) Sn-
1 alkyl chain profile in the individual cell lines of control and RCDP patients. C18:0 is reduced in all 
severely affected fibroblast lines, but not in the mildly affected ones. Error bars indicate standard 
deviations (n=3 for each individual cell line). (B) Overview of fatty alcohol composition in the 
different patient groups. Values represent means of all cell lines of the respective group. PM, 
plasmalogen
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3.1.3 Plasmalogen Loss Is Mainly Compensated by a Rise in 
Phosphatidylethanolamine Levels
Fibroblasts derived from severely affected RCDP patients have considerably lower amounts of 
plasmalogens than control cells. This observation led to the question, whether a loss of one major 
phospholipid class would provoke compensatory changes in the phospholipid profile of patient cells. 
Therefore, the main phospholipid classes were studied in RCDP 1-2 and RCDP 2-2, the fibroblast lines 
most severely affected by ether lipid deficiency, and compared with control lines (Figure 11). Levels 
of phosphatidylcholine and –serine did not differ from control cell values in patient cells. However, in 
case of phosphatidylethanolamine, a remarkable increase could be observed. The relative PE amount 
almost doubled from about 14-18% in control cells to 26-27% in plasmalogen-deficient cell lines. In 
contrast, sphingomyelin levels rather seemed to be decreased in cells lacking ether lipid synthesis. 
Thus, PE appears to be the only molecule replacing missing plasmalogens with the other main 
phospholipid classes remaining mostly unchanged. 
Figure 11: Compensatory mechanisms in ether lipid-deficient cell lines. Relative levels of 
phosphatidylcholine (A), sphingomyelin (B), phosphatidylethanolamine (C) and 
phosphatidylserine (D) in three control lines and two RCDP fibroblast lines severely affected by 
ether lipid deficiency. Lack of ether lipids is counterbalanced by a pronounced rise in 
phosphatidylethanolamine. Error bars indicate standard deviations (n=3 for each cell line). 
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Thus, it seemed likely that the total amount of ethanolamine phospholipids is kept at a constant level 
in cultured fibroblasts. In order to test this hypothesis, plasmenyl- and phosphatidylethanolamines 
were added up and the resulting values of control and patient cells compared to each other (see 
Figure 12). The results demonstrated that indeed the total amount of ethanolamine phospholipids 
was similar in patient fibroblasts and control cells. In all examined lines, ethanolamine phospholipids 
reached about 26-32% of the total phospholipid mass analyzed. However, the species accounting for 
these numbers were different between controls and patient cell lines; whereas in controls the ether-
containing ethanolamines (PL-PE) made up more than 40% of total ethanolamine phospholipids, this 
proportion was drastically reduced to about 5% in patient fibroblasts (Figure 12B). 
Figure 12: Compensation of plasmalogen deficiency by phosphatidylethanolamine. (A) The 
relative amount of total ethanolamine phospholipids is unchanged in cell lines lacking 
plasmalogens when compared with control cells (n=3 for each cell line). Error bars indicate 
standard deviations. (B) Distribution of ethanolamine phospholipids among plasmalogen and 
non-plasmalogen forms in control cells and ether lipid-deficient cells. PL-PE, 
plasmenylethanolamine; PE, phosphatidylethanolamine
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3.2 Batyl Alcohol and Hexadecylglycerol Are Highly Potent in 
Restoring Plasmalogen Levels in Culture
Peroxisomal plasmalogen synthesis can be bypassed by the application of a substance containing a 
glycerol backbone and a pre-formed ether linkage at the sn-1 position. Several publications report a 
rise in plasmalogen levels resulting from supplementation of cultured cells with batyl alcohol (BA, 1-
O-octadecyl-rac-glycerol) (Schrakamp et al., 1988) or 1-O-hexadecylglycerol (HDG) (Honsho et al., 
2010; Styger et al., 2002; Zoeller et al., 2002). Both of these compounds have a glycerol backbone, 
which is linked to a saturated C18 or C16 chain, respectively, via an ether bond at the sn-1 position. 
Therefore, supplementation with BA and HDG provides the cell with a utilizable ether lipid and 
enables the circumvention of the peroxisomal steps of ether lipid biosynthesis. To further elucidate 
the effects and the mechanism of action of these plasmalogen precursors, the phospholipid profile of 
treated fibroblasts was examined in more detail.
3.2.1 The sn-1 Alkyl Chain of Restored Plasmalogens Is Determined by the 
Structure of Their Precursors
A control fibroblast line and a patient line severely deficient in plasmalogen biosynthesis were 
treated with 20 µM HDG or BA for three consecutive days with medium changes every 24 hours. The 
respective cells under normal culture conditions and after treatment with ethanol, the solvent for BA 
and HDG, served as controls. In addition, the phosphate form of HDG (1-O-hexadecyl-2-hydroxy-sn-
glycero-3-phosphate; HDG-P) was evaluated concerning its ability to permeate cultured cells and 
restore plasmalogen levels. 
Results confirmed that all three tested compounds drastically increase the amounts of ethanolamine 
plasmalogens in cultured fibroblasts (see Figure 13A). Already in treated control cells, the levels were 
strongly elevated to about 150% (with BA and HDG-P) or even 200% (with HDG) compared with
untreated cells. 
In the ether lipid-deficient cell line, supplementation with the solvent ethanol alone did not show any 
beneficial effect. In contrast, treatment with all precursors raised plasmalogen amounts to values 
higher than those in untreated control cells. As in controls, HDG displayed a stronger potency to 
restore plasmalogens than BA. Supplementation with HDG led to levels of about 185% of control 
values, whereas BA treated fibroblasts reached about 130% of controls. A remarkably strong increase 
in ethanolamine plasmalogen amount was also observed in patient fibroblasts treated with HDG-P,
indicating that also this substance is highly efficacious in restoring plasmalogen levels in culture. 
In order to judge whether all fatty alcohol species are reconstituted in a similar way by precursor 
treatment, a closer look was taken at the alkyl chain distribution at the sn-1 position in treated cell 
lines. As already described in chapter 3.1.2, the sn-1 position of plasmalogens is occupied by either a 
16:0, an 18:0 or an 18:1 fatty alcohol, with the 16:0 species usually being the most prominent type. 
However, in fibroblast cultures supplemented with precursor lipids, the situation turned out to be 
different (see Figure 13B). Precursor treatment in every case recovered only one species, namely the 
one representing the chain length of the respective precursor; e.g. treatment with HDG resulted in 
an increase in only the 16:0 species. Plasmalogens containing other fatty alcohol species did not 
show elevated levels. This consequence of precursor treatment could be observed in control as well 
as in plasmalogen-deficient cells, with the effects being more pronounced in patient cells due to their 
very low basal plasmalogen amounts. 
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Therefore, these results demonstrate that the sn-1 position of plasmalogen precursors is not 
remodeled upon their metabolism to plasmalogens.
Figure 13: Reconstitution of plasmalogen levels by ether lipid precursors. (A) Treatment of 
control and plasmalogen-deficient patient fibroblasts increases ethanolamine plasmalogen 
amounts to values higher than those of untreated control cells. (B) Overview of alkyl chain
distribution at sn-1 position of ethanolamine plasmalogens after treatment with precursor lipids. 
Restored plasmalogens exhibit exclusively chain lengths that represent those of the precursor 
molecule used for treatment. All error bars indicate standard deviations (n=3 for each cell line 
and treatment with exception of HDG-P treatments, where n=1). EtOH, ethanol; BA, batyl 
alcohol; HDG, hexadecylglycerol; HDG-P, hexadecylglycero-phosphate; PM, plasmalogen
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3.2.2 Cellular Ethanolamine Phospholipid Levels Are Kept Constant upon 
Treatment with Plasmalogen Precursors
Plasmalogen precursor treatment of ether lipid-deficient fibroblasts restores plasmalogens to higher
than control levels. In order to determine if this drastic change also results in alterations in other 
phospholipid classes, the main phospholipids were exposed to further analysis. 
As was the case upon loss of plasmalogens, compensatory mechanisms following precursor 
treatment were mainly mediated by phosphatidylethanolamines (see Figure 14). In control as well as 
in patient cells, a profound reduction in the amount of PE could be observed after supplementation 
with BA or HDG. PE levels dropped from 15% and 27% of total phospholipids in untreated control and 
patient fibroblasts, respectively, to values of about 5% as a consequence of precursor administration. 
Contrary to PE, the levels of the other major phospholipid classes (phosphatidylcholine, 
sphingomyelin and phosphatidylserine) remained largely unchanged. Only in case of PC, a slight
decrease was discovered after HDG supplementation, which however was of minor significance 
compared with the dramatic changes in PE levels. Control treatment with ethanol alone did not 
provoke any phospholipid changes, confirming that the observed differences were indeed a 
consequence of precursor application.
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Figure 14: General phospholipid profiles after treatment of fibroblast cultures with 
plasmalogen precursors. Relative levels of phosphatidylcholine (A), sphingomyelin (B), 
phosphatidylethanolamine (C) and phosphatidylserine (D) in treated and untreated control and 
plasmalogen-deficient cells. The increase in ethanolamine plasmalogens provoked by precursor 
treatment is counterbalanced by a reduction of phosphatidylethanolamine levels. Error bars 
indicate standard deviations (n=3 for each cell line and treatment). EtOH, ethanol; BA, batyl 
alcohol; HDG, hexadecylglycerol 
As a similar compensation by PE had already been observed in cells deficient in ether lipid 
biosynthesis (see chapter 3.1.3), these results suggest a regulatory mechanism that maintains a 
constant level of ethanolamine phospholipids in the cell. To verify this assumption, plasmenyl- and 
phosphatidylethanolamines were summed up as described above and the total ethanolamine 
phospholipid amounts compared in precursor-treated and untreated fibroblasts (Figure 15). The 
resulting values were similar in all examined samples. In untreated or mock-treated fibroblasts, the 
major part of ethanolamines was made up by non-ether phospholipids. However, in cells supplied 
with ether lipid precursors, a high level of plasmalogen ethanolamines was found at the expense of 
the non-ether lipid form (see Figure 15B). Remarkably, total amounts of ethanolamine phospholipids 
were slightly lower in BA-treated fibroblasts (controls as well as patient cells) than in all others. 
Together with the compensatory mechanisms revealed in chapter 3.1.3, these results point to the 
fact that total ethanolamine phospholipids are kept constant under different circumstances – a rise 
in phosphatidylethanolamines accounts for a loss of plasmenylethanolamines and vice versa. 
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Figure 15: Compensation of a surplus of plasmalogens by phosphatidylethanolamine.
(A) Overview of total ethanolamine phospholipid levels in treated and untreated control and 
RCDP fibroblasts. Reduction of PE counterbalances the rise in PL-PE following ether lipid
precursor treatment, leading to rather similar total ethanolamine values in all treated and 
untreated cell lines. Error bars indicate standard deviations (n=3 for each cell line and treatment). 
(B) Distribution of ethanolamine phospholipids among plasmalogen and non-plasmalogen forms 
in treated and untreated control and ether lipid-deficient cells. EtOH, ethanol; BA, batyl alcohol; 
HDG, hexadecylglycerol; PL-PE, plasmenylethanolamine; PE, phosphatidylethanolamine
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3.3 Peroxisomal Ether Lipid Synthesis Is Not Required for Surface 
Expression of the GPI-Anchored Protein Thy-1 in Mammals
As alkylacylglycerol-containing GPI anchors cannot be formed under conditions of ether lipid 
deficiency, the question was addressed whether or not the surface localization of GPI-anchored 
proteins is affected by the loss of ether lipids. Two different model organisms were employed for this 
approach: On the one hand, cells obtained from an ether lipid-deficient mouse, the DAPAT knockout 
(ko) mouse (Rodemer et al., 2003), were analyzed. On the other hand, surface expression of a GPI-
anchored protein was studied in primary fibroblast cultures derived from patients suffering from 
RCDP (see chapter 3.1).
3.3.1 Surface Localization of Murine Thy-1
Analysis of Murine Genotypes
Because DAPAT (-/-) mice are infertile, heterozygous animals were mated to produce homozygous 
mutant offspring. Thus, in order to study cells of ether lipid-deficient mice, as a prerequisite, their 
genotype had to be determined. This was done routinely by a PCR approach using DNA obtained 
from mouse tails or cultured cells: In DAPAT ko mice, exons 5-7 of the DAPAT gene are replaced by a 
DAPAT/neomycin cassette (Rodemer et al., 2003), which can be easily detected and discriminated 
from the wild type (wt) allele with the help of the corresponding PCR primers. Subsequently to PCR 
reactions, the samples were applied to a 1.5% agarose gel containing ethidium bromide. Band sizes 
visible upon UV exposition indicated the genotypes of the corresponding samples. Figure 16 shows a 
representative example of a standard DAPAT genotyping assay, identifying the genotypes of two ko 
mice (M1, M6), one wt mouse (M2) and three heterozygotes (M3, M4, M5). 
Figure 16: Representative example of PCR determination of DAPAT genotypes. Larger bands 
(∼860 bp) indicate the presence of a ko allele, whereas smaller fragments (∼650 bp) result from
amplification of the wt allele. M, mouse
In addition to the DAPAT genotype, also the Thy-1 genotype of the mice studied needed to be 
identified. In mice, two alleles of Thy-1 exist, which code for the Thy-1.1 and the Thy-1.2 
glycoprotein, respectively. These two differ only in a single amino acid at position 89, arginine in Thy-
1.1 and glutamine in Thy-1.2 (Williams and Gagnon, 1982), due to a single nucleotide polymorphism 
(SNP) in the murine Thy-1 gene. Only very few mouse strains, for example AKR/J, A or Thy-1.1, 
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express the Thy-1.1 allele. However, most strains, including the abundant ones C57BL/6 or Swiss, 
possess the Thy-1.2 epitope. In contrast, rat Thy-1, which is highly homologous to the murine 
protein, is solely of the Thy-1.1 type.
The mice employed in Thy-1 surface localization experiments were of mixed background meaning 
that their genotype concerning Thy-1 was uncertain. Due to the fact that a Thy-1.2-specific antibody 
was used for immunofluorescence studies, the presence of this epitope had to be demonstrated
prior to staining experiments. In order to distinguish between Thy-1.1 and Thy-1.2, an allele-specific 
PCR assay was established with downstream primers that selectively address the difference between 
the two variants (see Figure 17A). In addition, the primers were designed in a way that rat DNA could 
serve as a positive control for Thy-1.1 (see Figure 17B). Genotyping samples were routinely checked 
on 1.8% agarose gels (see Figure 17C for an example). As illustrated, mice expressing the Thy-1.1 
(M1, M3) variant were as well identified as mice harboring the Thy-1.2 antigen (M2, M4). The 
detection of Thy-1.1 only in rat DNA (RT1, RT2) revealed the successful establishment of the assay. 
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Figure 17: Thy-1 genotyping. (A) Murine Thy-1 gene structure (source: 
http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly). Primers employed for genotyping are 
indicated as green arrows. SNP, single nucleotide polymorphism; (B) Strategy for reverse primer 
design. Allele-specific primers were constructed in a fashion complementary to the coding strand. 
The Thy-1.1/1.2 SNP is indicated by a red arrow; a one-base-pair mismatch (depicted in blue) was 
introduced to increase selectivity of the primer for the corresponding allele. Mismatches 
displayed in green were deliberately accepted to enable the recognition of both rat and mouse 
DNA. Ms, mouse; (C) Representative example of Thy-1 genotype determination. Fragments of 
∼270 bp indicate the presence of the respective allele (Thy-1.1 or Thy-1.2); M, mouse; RT, rat
Immunofluorescent Staining of Thy-1
Murine wt and DAPAT ko embryonic fibroblast lines (MEFs) carrying the allele coding for Thy-1.2
were employed for fluorescent staining of Thy-1. Immunofluorescence was performed as described 
(see chapter 2.2) and the cells visualized using fluorescence microscopy. Based on the fact that the 
protocol used does not involve any permeabilization step, which would permit antibody entry into 
the cytoplasm, the observed staining resulted exclusively from binding of antibodies to molecules on 
the outer membrane surface. 
Immunofluorescent detection of Thy-1.2 revealed an intense punctate staining of wt as well as ko 
fibroblasts (see Figure 18). This indicates that, in spite of the failure to synthesize alkylacylglycerol, 
the GPI-anchored Thy-1 is successfully delivered to the plasma membrane under ether lipid-deficient 
conditions.
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Figure 18: Surface expression of Thy-1 in murine embryonic fibroblasts. Thy-1 is clearly visible 
on the surface of both wt (A) and DAPAT ko (B) fibroblasts. An antibody control (secondary 
antibody only) is shown in (C). Original magnification: 60x; scale bars: 20 µm 
The punctate distribution of Thy-1 on the surface is highly likely to indicate the distribution of Thy-1-
containing membrane rafts. Based on this, it is of notice that in ko fibroblasts the space between 
individual dots seems to be larger than in wt cells, probably pointing to the fact that ko fibroblasts 
have fewer Thy-1-positive rafts. In addition, the average size of single Thy-1 spots appears slightly
larger in ko MEFs, which could suggest larger rafts resulting from fusion of smaller domains.
In addition to fibroblasts, Thy-1 surface expression was also analyzed in murine T cells. For this 
purpose, a drop of blood was drawn from the tail tip of 18-20 days old mice after biopsy for 
genotyping and streaked onto microscopic glass slides. Staining was carried out as described in the 
“Methods” section (cf. chapter 2.2). Again, only proteins on the outer cell surface were detected. 
Immunofluorescence microscopy showed a nice surface staining of T cells in blood of wt and ko mice 
without any visible differences between the different genotypes (Figure 19). Erythrocytes, by far the 
most abundant cells in the blood, surrounding stained T cells did not express Thy-1 and were
therefore not labeled in this experiment. Out of 38 ko mice examined, all exhibited Thy-1 surface 
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positive T cells confirming that mice deficient in ether lipid biosynthesis are generally able to 
transport GPI-anchored proteins efficiently to the external face of the plasma membrane. 
Figure 19: Surface expression of Thy-1 in blood streaks derived from control (A) and DAPAT ko 
(B) mice. Thy-1 is highly abundant on the surface of both wt and ko T cells. In contrast, 
surrounding erythrocytes do not express Thy-1 and are therefore not stained. Original 
magnification: 60x; scale bars: 20 µm
3.3.2 Surface Localization of Human Thy-1
In order to evaluate, if also in humans affected by ether lipid deficiency GPI anchors are properly 
directed to the plasma membrane, the respective patient fibroblasts were stained for Thy-1 in a 
similar fashion as described for murine cells. The RCDP patient cell line 2-2 was chosen as most 
suitable model for this experiment due to the very low plasmalogen content of these cells in culture 
(see chapter 3.1.1) and the severe phenotype of the respective patient. 
Again, staining was performed without any permeabilization to examine surface exposition of the 
Thy-1 antigen. Similar to what had been observed in mouse fibroblasts, Thy-1 was found to be 
expressed and transported to the surface by fibroblasts deficient in ether lipid synthesis. Staining for
the GPI-anchored protein in RCDP patient cells revealed a pattern that closely resembled that in 
control fibroblasts (see Figure 20). In patient fibroblasts, as in murine DAPAT ko fibroblasts, the 
average size of the individual, differentiated dots, probably indicating raft structures, appeared a 
little larger than in controls. However, from the results of these studies, it can be concluded that 
ether lipid synthesis is not necessary for the expression and surface localization of GPI-anchored 
proteins in murine or human cells. 
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Figure 20: Surface expression of Thy-1 in human fibroblasts. Thy-1 is expressed on the surface of 
both control cells (A) and fibroblasts deficient in ether lipid biosynthesis (B). An antibody control 
is depicted in (C). Original magnification: 40x; scale bars: 50 µm
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3.4 Relative Amounts of Some Membrane Raft Proteins Are
Dysregulated in Ether Lipid-Deficient Human Fibroblasts
Plasmalogens are essential constituents of cellular membranes, especially of membrane rafts. 
Therefore, it can be assumed that, upon deficiency of ether lipids, membranes undergo some 
rearrangement in order to compensate for the loss of these molecules. To determine, if any of these 
changes affect the levels of raft- and non-raft-associated membrane proteins in human patients, 
RCDP fibroblast cell lines were subjected to western blot analysis.
For this purpose, total proteins were prepared from three normal human fibroblast lines and two 
lines each derived from patients suffering from the mild (cell lines RCDP 2-1 and RCDP 3-1; cf. Table 
1) and severe form (cell lines RCDP 2-2 and RCDP 1-2) of RCDP, respectively. Protein contents were 
determined by the Bradford assay, equal amounts of protein loaded onto SDS gels and protein levels 
examined by western blot analysis (Figure 21). 
Figure 21: Western blot analysis of membrane protein amounts in total extracts of human 
fibroblasts. The relative amounts of a membrane-associated raft protein (flotillin-1) (A), a 
membrane-spanning raft protein (connexin 43) (B), GPI-anchored proteins (Thy-1, CD55) (C) and 
a non-raft transmembrane protein (transferrin receptor) (D) were determined. C1-C3 indicate 
control lines; 2-1 and 3-1 belong to the “mild disease course” group; 2-2 and 1-2 are fibroblasts 
derived from patients with most severe plasmalogen deficiency. Separating gel concentrations 
varied from 9% to 12% acrylamide, applied protein amounts were between 7 and 25 µg 
(according to the protein to be detected). After detection of membrane proteins, the same blots 
were reprobed for β-actin as a loading control. β-Act, β-actin
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In order to obtain a rather complete picture, the examined proteins included: 
• A membrane-associated raft protein, flotillin-1, whose connection with the plasma 
membrane is dependent on its palmitoylation (Morrow et al., 2002);
• a membrane-spanning raft protein, connexin 43 (Cx43), containing four transmembrane 
domains (Goodenough et al., 1996);
• GPI-anchored proteins, Thy-1 and CD55; and
• a transmembrane protein known not to be associated with membrane rafts (transferrin 
receptor). 
Although the relative levels of several proteins appeared to be rather heterogeneous already in the 
three control lines, some remarkable irregularities could be observed, especially in severely affected
patient fibroblasts (see Figure 21). Flotillin-1 seemed to be enriched in two of the cell lines defective 
in DAPAT (RCDP 2-1 and 2-2), but not in any other fibroblast line deficient in ether lipid synthesis. 
Surprisingly, a similar pattern was observed for the non-raft marker transferrin receptor – probably 
these two cell lines generally contain a higher amount of membrane proteins in relation to cytosolic 
ones. Striking abnormalities were found in case of the transmembrane protein connexin 43: 
Compared to controls, the protein was almost absent in cell line RCDP 2-2. Additionally, reductions 
were also determined in the second line derived from a severely impaired patient (RCDP 1-2) and a 
mildly affected line (RCDP 3-1). In mammals, Cx43 occurs in three different phosphorylation states 
(Musil et al., 1990) leading to three slightly distinct bands (partly visible in Figure 21 and Figure 22). 
All three variants were affected equally by the loss of Cx43 and there was no observable difference in 
phosphorylation state between control and plasmalogen-deficient cell lines.
Both of the examined GPI-anchored proteins were rather hard to detect in total cell extracts (partly 
because of the background produced by the antibodies used). Nevertheless, abnormalities in their 
relative amounts were again discovered in cell lines derived from severely impaired patients. Thy-1 
showed rather equal intensities in all cell lines except RCDP 2-2, in which it was almost absent. In 
contrast, CD55 seemed to be reduced in both severely affected lines. However, the levels in three 
different control lines exhibited a remarkable variability as well. Taken together, dysbalances in 
membrane protein amounts were observed in plasmalogen-deficient cell lines and were particularly 
pronounced in a cell line defective in the DAPAT protein (RCDP 2-2). 
In order to exclude the possibility of different cell sizes leading to varying amounts of membrane 
proteins and to avoid the high background level produced by some antibodies in total extracts, crude 
membrane preparations of the same cell lines were performed to confirm the obtained results. Equal 
protein amounts were again applied to SDS gels and analyzed by immunoblotting (see Figure 22). The 
non-raft protein transferrin receptor served as loading control in spite of the fact that its levels
seemed to be slightly variable in total extracts. 
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Figure 22: Western blot analysis of membrane protein amounts in crude membrane 
preparations of human fibroblasts. The relative amounts of a membrane-associated raft protein 
(flotillin-1) (A), a membrane-spanning raft protein (connexin 43) (B) and GPI-anchored proteins 
(Thy-1, CD55) (C) were determined. C1-C3 indicate control lines; 2-1 and 3-1 belong to the “mild 
disease course” group, and 2-2 and 1-2 are fibroblasts derived from patients with most severe 
plasmalogen deficiency. Separating gel concentrations varied from 9% to 12% acrylamide, applied 
protein amounts were between 5 and 8 µg (according to the protein to be detected). After 
detection of raft proteins, the same blots were reprobed for TfR as a loading control. The 
displayed results are representative of two independent preparations. TfR, transferrin receptor
The results illustrated in Figure 22 were in good agreement with the findings of western blot analysis 
in total extracts. Flotillin-1 levels in membrane preparations appeared rather similar in all cell lines 
with slightly stronger bands visible in the two DAPAT-deficient fibroblast lines RCDP 2-1 and RCDP 2-
2. Concerning the amounts of Cx43, obvious differences were visible as already observed in the total 
extract. Cell line RCDP 2-2 exhibited very low Cx43 levels in the membrane-enriched fraction 
compared with all other lines. In addition, the amounts were clearly decreased in lines RCDP 3-1 and 
RCDP 1-2. 
Both examined GPI-anchored proteins (Thy-1 and CD55) were severely reduced in RCDP 2-2. 
However, the second cell line derived from a patient with severe disease course, RCDP 1-2, did not 
show any noticeable differences in comparison with control and mildly affected cell lines. The latter 
behaved like control cells in all cases with exception of Cx43 levels in line RCDP 3-1.  
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3.5 Thy-1 Associates with Membrane Rafts, But Floats to Slightly 
Higher Density in Ether Lipid-Deficient Human Fibroblasts
When being integrated into the plasma membrane, GPI-anchored proteins are thought to be 
selectively targeted to membrane raft domains (see chapter 1.4). In ether lipid-deficient cell lines, 
the lipid portion of the GPI anchor does not contain the ether form alkylacylglycerol. The 
consequences of this defect for the membrane distribution of these proteins are still unclear. In 
chapter 3.3.2, it was shown that association with the plasma membrane is still possible in human 
RCDP fibroblasts that are severely defective in ether lipid synthesis. However, the correct localization 
of GPI-anchored proteins to membrane rafts cannot be determined, but only hypothesized from 
immunofluorescence methods. Instead, biochemical approaches are required to get an insight into 
the raft association of the GPI anchor under conditions of ether lipid deficiency. 
Therefore, the concept of detergent-resistant membranes (DRMs) was applied to RCDP and control 
fibroblasts. Three control cell lines and two lines each derived from mildly affected RCDP patients 
and RCDP patients with a severe phenotype, respectively, were tested concerning the DRM 
association of a GPI-anchored protein. Fibroblasts were lysed in 1% Triton X-100 and, subsequently, 
DRMs were isolated by density gradient centrifugation as described (see chapter 2.2.3). DRMs are 
characterized by their flotation abilities, meaning that – after lysis – during centrifugation they float 
to the light fractions at the top of a sucrose gradient (see Figure 7). However, in every DRM 
experiment, the presence of raft-like structures in the top fraction has to be proven by a marker 
protein, which is typical of these membrane subdomains. Here, flotillin-1, a widely used raft marker 
(Morrow and Parton, 2005), was used for this purpose. In contrast, the transferrin receptor (TfR) was 
engaged as marker of the non-raft membrane fraction. A constant number of confluent cell culture 
dishes was utilized for density gradient experiments; the protein amount loaded onto SDS gels for 
analysis was normalized by determining the total protein content of all gradient fractions. Equal 
volumes of the fractions originating from the same gradient were applied and the exposure times for 
development of western blots kept in similar ranges throughout the whole experiment. In all 
gradients, protein content proved to be very low and hardly detectable by a classical Ponceau 
staining in the top (=DRM) fractions. In contrast, high amounts of protein were detected in the 
detergent-soluble fractions. This is in line with literature about DRM isolation, which states that –
compared to the total amount of protein in a cell – a very minor part of proteins is DRM-associated. 
Figure 23A shows the distribution of the raft marker (flotillin-1), a GPI-anchored protein (Thy-1), 
which – at least under normal conditions – is supposed to localize to membrane rafts as well, and the 
non-raft marker (TfR) in control fibroblast cell lines. Flotillin as well as Thy-1 are almost exclusively 
found in the topmost fractions of the gradient, whereas transferrin receptor is located in the 
lowermost fractions, where all detergent-soluble proteins, including cytosolic and non-raft 
membrane proteins, are expected. A third control cell line showed identical results with regard to the 
distribution of all three examined proteins (data not shown). However, in all controls also some
flotillin was detected in detergent-soluble fractions.
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Figure 23: Western blot analysis of DRMs isolated from control (A) and RCDP fibroblast cell 
lines representing the mild (B) and the severe (C) form of the disease. Twelve fractions were 
collected from each sucrose gradient from the top; “1” indicates the lightest fraction. For 
illustration, only the top four fractions (1-4; detergent-resistant material), one medium density 
fraction (7) and the three lowest fractions (10-12; detergent-soluble material) are shown. Thy-1 is 
heavily glycosylated and appears therefore as a smear rather than a distinct band. Concentration
of separation gel: 12% acrylamide. All three examined proteins were detected on the same blots 
by stripping and reprobing with the corresponding antibodies. Total protein amounts were equal 
in all SDS gels; equal volumes of the fractions originating from the same gradient were applied.  
Flot-1, flotillin-1; TfR, transferrin receptor
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Fibroblasts representing the mild and severe form of RCDP (Figure 23B and C, respectively) exhibited 
a somewhat different distribution of marker and GPI-anchored proteins. Although TfR was present in 
the lowermost fractions and largely excluded from the DRM fractions as was the case in control lines, 
RCDP cell lines differed from control lines with respect to the localization of raft proteins. Flotillin 
distribution was rather similar to control cell lines with exception of line RCDP 2-2 (carrying 
mutations in the GNPAT gene), in which the amount in detergent-soluble fractions was 
approximately equal to that in the detergent-resistant portion. Thy-1, however, showed an increased 
tendency to shift to fractions of higher density, which could be observed in cells derived from mildly 
as well as severely affected patients. Whereas in control cells Thy-1 was only detectable in the 
lightest two fractions, it was distributed over more, if not all fractions in RCDP cell lines, even though 
the highest amounts were still present in the top fractions. In all four patient fibroblast lines, signals
were clearly visible in fraction 3 (where no Thy-1 was detected in controls) and traces even in 
fractions 10-12. 
Taken together, these results suggest differences in the DRM-association of the representative GPI-
anchored protein Thy-1, which, however, demand further confirmation by additional DRM 
experiments.
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3.6 Formation of the Neuromuscular Junction Is Modified in the 
DAPAT Ko Mouse
Continuous observation of their behavior in the cage shows profound deficiencies of the motor 
system in DAPAT (-/-) mice. Teigler and collaborators indicated weak performance of these mice in 
several behavioral tests that also involve motor function, but no data are provided (Teigler et al., 
2009). Thus, in the following approach, motor deficiencies were first confirmed and scored using 
motor-behavioral tests. In order to study the mechanisms underlying the motor deficits, a closer look 
was then taken at the neuromuscular junction (NMJ), a structure, where the synapses between 
motor nerves and muscle fibers are formed. NMJ formation was studied in vitro by using myotubes 
derived from DAPAT ko mice. 
3.6.1 DAPAT Ko Mice Show Abnormalities in Motor Ability 
Two different age cohorts (3-4 months, 7 months) of male mice were subjected to testing on an 
accelerating Rotarod treadmill and on a balance beam. 
Rotarod
The latency to fall off an accelerating Rotarod apparatus was measured in order to evaluate motor 
coordination abilities. Experiments revealed apparent differences in motor skills between DAPAT ko 
and age-matched wt mice (see Figure 24) that, however, were not statistically significant according 
to a Mann-Whitney rank sum test (P=0.189 for 3-4 months old mice; P= 0.140 for 7 months old mice). 
Observations suggested that ko mice – probably due to their impaired visual abilities and overall 
physical handicaps – stayed much more focused on their task, while wt mice spent more time 
exploring their surroundings (especially at the beginning of the test) and therefore suffered early falls 
in some cases.
A B
Figure 24: Motor behavior of 3-4 months old (A) and 7 months old (B) DAPAT ko and wt mice 
on an accelerating (4-40 rpm) Rotarod treadmill. Box plot graphics show the median values; 1st 
and 3rd quartiles (50% of values) are boxed, whiskers indicate highest and lowest values within 
1.5 times the interquartile range. For statistical analysis, Mann-Whitney rank sum test was used
(3-4 months: P=0.189; 7 months: P=0.140). 
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Overall, the mean value of performance in wt mice stayed relatively similar – though more variable –
in older animals compared with younger ones, whereas motor behavior of older ko mice was slightly 
poorer than that of younger ones, which, however, exhibited considerable variation. 
Balance Beam
The performance in the trials of age-matched wt and ko mice on the balance beam, a wooden rod of 
about 2 cm diameter, that they had to cross three times, was judged according to a scoring system as 
indicated in Table 2. 
Score Description
1 Performs task without problem, stepping with all four paws on top quarter of the rod
2 Performs task, slipping with hind paws below top quarter of the rod
3 Performs task, slipping with hind paws below midline of the rod
4 Performs task poorly, dragging hind limbs below midline or slipping with front and 
hind limbs below midline
5 Cannot perform task; falls off the beam
Table 2: Scoring system for evaluation of performance on the balance beam; grading steps of 0.5 were 
employed for more exact evaluation (e.g. 2.5 for occasional slipping below the midline)
Differences between wt and ko animals (age cohorts as described above) were clearly visible on the 
balance beam and also proved to be highly significant (P<0.001 for age 3-4 months; P=0.003 for age 7 
months). Although wt mice appeared to be timid as well, when first confronted with the balance 
beam task, which is likely to be due to their sparse movement associated with caging, they were 
mostly able to cross the bar without any problems and with their feet mainly above the drawn 
midline (see Figure 25). In contrast, DAPAT ko mice displayed marked deficits in motor ability during 
the balance beam test. Most of them could not cross the bar in a proper fashion, many refused to 
cross the rod at the beginning of the training sessions. Additionally, ko mice were not able to keep 
their hind limbs on the top of the beam (above the midline). Instead, their hind feet slid down 
repeatedly, leading to forward movement in a crawling manner while straddling the rod. Some ko
animals completely failed to execute the task, as they quickly fell off the bar even after several 
training efforts. 
Regarding both ko and wt mice, motor performance decreased with higher age, while the relative 
differences between the two groups (wt; ko) stayed comparably similar. 
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Figure 25: Motor skills of wt and DAPAT ko mice on the balance beam. (A) Performance of wt 
mice (7 months) on the beam: Mice cross the rod quickly after learning, with their hind limbs 
usually above the midline. (B) Performance of ko mice (7 months) on the beam: Hind limbs are 
usually below the midline and the mice rather crawl than run across the rod. (C) Overall balance 
beam performance of 3-4 months old (left) and 7 months old (right) wt and DAPAT ko mice; 
statistical differences were highly significant (P<0.001 for age 3-4 months, P=0.003 for age 7 
months) upon analysis using Mann-Whitney rank sum test.  
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3.6.2 Smaller Acetylcholine Receptor Clusters Are Formed in DAPAT Ko
Myotubes
To evaluate the proper in vitro formation of agrin-elicited acetylcholine receptor (AChR) clusters, 
which mimics the development of a neuromuscular junction, primary myoblasts were isolated from 
newborn DAPAT ko and control mice. Myoblasts were, as far as possible, separated from fibroblasts
and kept in culture for a few days until they reached confluency, meaning that the cellular processes 
were in close proximity to each other. Fusion of myoblasts, similar to the formation of muscle fibers 
in vivo, was induced by a switch to differentiation medium. Progress in the formation of myotubes as
a result of myoblast fusion was observed by light microscopy. After two to three days of 
differentiation, clustering of AChRs, which, in the living organism, are crucial for the regulation of 
electrical activity and the contractile state of the muscle, was induced by addition of recombinant 
agrin to the medium. Agrin is a 200 kDa protein, which is deposited by nerve cells and has been 
shown to cause clustering of pre-existing AChRs on the surface of cultured myotubes (Godfrey et al., 
1984; McMahan, 1990), an effect that is mediated by the receptor tyrosine kinase MuSK (muscle 
specific kinase) (Glass et al., 1996). After overnight stimulation with agrin, AChR clusters were stained 
with fluorescent-dye-???????? ?-bungarotoxin, which binds irreversibly to muscular AChR, and 
visualized by fluorescence microscopy.
During culturing, myoblasts derived from ko animals seemed to exhibit slower growth than those 
derived from wt mice. Total numbers of isolated myoblasts were lower as well, which, however,
could also be a consequence of incidental differences in the isolation procedure. In addition, overall 
size of myotubes appeared smaller in ko cultures, which could be assigned to differences in myoblast 
numbers. However, although these differences were noticed in several isolations, they were not 
quantified and can therefore only serve as preliminary observations. 
Staining of AChRs revealed that agrin-induced clusters can be as efficiently formed in myotubes 
derived from ko animals as in wt myotubes (see Figure 26A and B for a representative example). 
Quantification of cluster size (in terms of length) and number in the different cultures was executed 
by fluorescence microscopic tools. The summary of one representative experiment is indicated in 
Figure 26C and D: Although cluster length values showed a relatively great variation, slight 
differences could be discovered between wt and ko cultures. However, these did not reach statistical 
significance in this experiment (P=0.093). In contrast, the number of clusters (in relation to the length
of myotubes) was not changed between the two groups. The observed small difference in the mean 
value in this case is highly likely to be due to random sampling variability (P=0.861). 
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Figure 26: Formation of acetylcholine receptor clusters in cultured murine myotubes.
Fluorescence microscopic analysis of AChR clusters ????????????? ?-bungarotoxin in wt (A) and 
DAPAT ko (B) myotubes. There are no apparently visible differences in cluster formation and 
shape between knockout and control cultures. Original magnification of microscopic images: 63x. 
(C) Quantification of AChR cluster size (length) in cultured myotubes. Total numbers of evaluated 
clusters were 39 in case of the wt and 33 in case of the ko culture. Mean values are depicted with 
error bars representing S.E.M. values. Statistical analysis was carried out using a two-tailed 
Student’s t-test (P=0.093). (D) Cluster number in relation to myotube length. Numbers of 
evaluated myotubes were 19 in each case. Mean values are depicted with error bars representing 
S.E.M. values. Statistical analysis was carried out using Mann-Whitney rank sum test (P=0.861). 
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CHAPTER 4
4DISCUSSION
The present thesis is intended to contribute to the clarification of the role of ether lipids in 
physiological and pathological processes. Notably, the material used is derived directly from either 
human patients suffering from ether lipid deficiency or a corresponding mouse model and is 
therefore in close relation to the respective disease, RCDP. Ultimately, this and further studies should 
bring us closer to the understanding and – as a consequence – the cure or at least a relief of this 
severe disease. 
In the course of this work, the general phospholipid profiles of control fibroblasts and 
fibroblasts deficient in ether lipid biosynthesis were examined. In controls, PC was identified as the 
major phospholipid species with the remaining phospholipid mass quite equally shared among PE, 
PS, SM and PL-PE. The values obtained are mainly in line with recent publications reporting 
phospholipid composition in fibroblasts (Murphy et al., 2006; Murphy et al., 2000b; Styger et al., 
2002). Only the percentage of PS described in literature tends to be a bit lower than that in the 
present work. 
A main focus of this diploma thesis was on the examination of plasmalogens in fibroblasts derived 
from RCDP patients. Nowadays, RCDP is reported as a disease with rather heterogeneous 
appearance especially concerning its severity. Many affected children do not survive their first years 
of life, whereas others display only some of the typical RCDP symptoms and reach a more advanced 
age. For the present study, three different skin fibroblast lines derived from patients who suffered 
from such a mild form of the disease were available. Line RCDP 1-1 harbors one allele with a non-
functional copy of PEX7 (L292X mutation; see below); the second allele carries a different mutation
(H285R), which is supposed to enable normal folding of the protein, but leads to decreased affinity 
for binding partners (Braverman et al., 2002). In cell line RCDP 2-1, a homozygous mutation in one of
the splice donor sites of the GNPAT gene induces impaired splicing of the mRNA, resulting in a milder 
form of RCDP due to residual DAPAT activity. Finally, in cell line RCDP 3-2, which carries a 
homozygous AGPS mutation, AGPS appears largely degraded but displays residual activity, as has 
been concluded from the rate of plasmalogen biosynthesis (Itzkovitz et al., 2009). Lipidomic analysis
in this work revealed a significant reduction of plasmenylethanolamines in all three mutant cell lines 
when compared with controls. The obtained values were between 50 and 70% of the control mean. 
This is in good agreement with the observation that the degree of plasmalogen deficiency 
determines disease severity (Braverman et al., 2002). Plasmalogens in mildly affected fibroblasts are 
markedly reduced, but still a considerable amount of these lipids is present to fulfill its functions. 
However, compared with the present analysis, other publications describe slightly lower plasmalogen 
levels in patients with mild RCDP, e.g. Braverman and collaborators report plasmalogen levels of 
∼30% in red blood cells (RBC) of these individuals (Braverman et al., 2002). Besides, a mouse model 
representing the mild variant of RCDP exhibits 30-50% RBC plasmalogen levels as compared to 
controls (Braverman et al., 2010). In addition to fibroblasts of mildly affected patients, four fibroblast 
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lines derived from patients suffering from severe RCDP were analyzed: Cell lines RCDP 1-2 and 1-3 
each express two non-functional copies of PEX7. In cell line RCDP 2-2, a homozygous single base pair 
deletion in exon 10 of the GNPAT gene was identified and shown to be the consequence of paternal 
isodisomy of chromosome 10 (Nimmo et al., 2010). The fourth severely affected fibroblast line (RCDP 
3-2) carries a homozygous AGPS mutation rendering the AGPS protein non-functional (Itzkovitz et al., 
2009). Interestingly, all of these cultures exhibited severely reduced, but still substantial amounts of 
plasmenylethanolamines. Furthermore, two of the cell lines (RCDP 1-3 and RCDP 3-2) rather behaved 
like cells of the “mild course” group, as they displayed plasmalogen levels of about 40% of the 
control mean, whereas the other two severely affected lines (RCDP 1-2 and RCDP 2-2) reached only 
∼15%. 
In principle, complete deficiency in plasmalogen biosynthesis was expected in all fibroblast lines 
derived from RCDP patients of the “severe course” group, as all of them carry mutations that fully 
inhibit the peroxisomal steps of ether lipid formation. The high value measured for cell line RCDP 1-3 
is especially surprising, as these fibroblasts carry the L292X mutation in both PEX7 alleles. This 
mutation is found at extraordinarily high frequency in RCDP type I patients (Braverman et al., 1997; 
Brites et al., 1998), which has been shown to be the result of a founder effect in a Caucasian 
population (Braverman et al., 2000). Although near normal mRNA levels are produced, the resulting 
protein has been proven to be non-functional (Braverman et al., 2002; Motley et al., 2002). The high 
plasmalogen levels obtained are also surprising with regard to the results of Braverman et al. and 
Nimmo et al., who found nearly non-detectable rates of RBC plasmalogens and plasmalogen 
biosynthesis in fibroblasts of patients homozygous for the deleterious L292X mutation and the RCDP 
type II patient carrying the homozygous deletion in the GNPAT gene (cell line RCDP 2-2) (Braverman 
et al., 2002; Nimmo et al., 2010). However, in cultured cells deficient in ether lipid biosynthesis, 
residual amounts of plasmalogens have been observed by other groups as well: CHO cells defective 
in DAPAT or AGPS exhibit plasmenylethanolamine levels of about 10% of the wild type level (Mankidy 
et al., 2010; Nagan et al., 1997). Moreover, almost 50% of the control PL-PE value was demonstrated 
in fibroblasts of Zellweger patients, which due to their inability to assemble peroxisomes should also 
be highly deficient in synthesizing ether lipids (Styger et al., 2002). From these observations, the 
question of the origin of these residual plasmalogens under conditions of deficient ether lipid 
synthesis arises. Possibly, an alternative, non-peroxisomal pathway of ether lipid synthesis exists e.g. 
involving a non-peroxisomal DAPAT activity, like the one described by Schlossman and Bell 
(Schlossman and Bell, 1976, 1977). Alternatively, in case of PEX7 mutations, some AGPS could be 
transported to the peroxisome in a complex with DAPAT in a PEX5-dependent fashion. Such a “piggy-
back” mechanism would be PEX7-independent and would occur also in the absence of the functional 
PTS2 receptor. However, both of the mentioned possibilities seem rather unlikely, as they do not 
account for the low plasmalogen levels found in RBCs of patients and the low plasmalogen 
biosynthesis rate in fibroblasts. Instead, it appears highly probable that cultured cells can take up 
plasmalogens or ether lipid precursors, which are utilizable for plasmalogen biosynthesis, from the
culture medium containing FBS. This explanation is also in line with the observation that cell lines 
RCDP 1-3 and RCDP 3-2 exhibited slower growth in culture: more slowly dividing cells could 
incorporate higher amounts of plasmalogens from the medium, before they have to “share” the 
lipids with their daughter cells. To prove this assumption, the use of plasmalogen-free culture 
medium (e.g. synthetic FBS substitution products) would be required and is intended for future
experiments involving ether lipid-deficient fibroblasts. Nevertheless, the findings made in this study 
reveal significant differences in ethanolamine plasmalogen levels between healthy controls, patients 
suffering from the mild form of RCDP and patients affected by the severe form of the disease. 
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Concerning the fatty alcohol distribution at the sn-1 position of ethanolamine plasmalogens, mass 
spectrometric analysis identified C16:0 as the predominant species followed by C18:0 and C18:1. This 
is basically in accordance with the values reported in a similar experiment with wild type CHO cells
(Mankidy et al., 2010). However, the pattern of the different alkyl chains was rather diverse in three 
different control lines, pointing to a rather random incorporation at the sn-1 position. The sn-1 chain 
in plasmalogens is determined by a fatty alcohol introduced by AGPS. This alcohol is predominantly 
produced by the fatty acyl-CoA reductase, Far1 (Honsho et al., 2010), which preferably uses 
saturated and monounsaturated fatty acyl-CoAs with chain lengths of 16 or 18 carbon atoms as 
substrates (Cheng and Russell, 2004), at the outer peroxisomal membrane surface. The alkyl chain
distribution at the sn-1 position in the examined control lines therefore rather reflects the incidental 
availability of fatty acyl-CoAs used by Far1 than a predetermined pattern of fatty alcohol 
incorporation. However, in all fibroblast lines of severe RCDP patients, there was a consistently lower 
percentage of C18:0 at the sn-1 position. In case the residual plasmalogen levels of these cell lines 
were derived from remaining cellular biosynthesis mediated by a “piggy-back” mechanism or an 
alternative pathway, the offered sn-1 profile points towards either a different availability of fatty 
acids under conditions of defective peroxisomal ether lipid biosynthesis or – in case of an alternative 
pathway – a different substrate specificity of one of the involved enzymes. On the other hand, if 
RCDP fibroblasts utilize precursors or plasmalogens provided by the culture medium, the observed 
pattern at the sn-1 position might just represent the structure of the provided molecule, as the sn-1 
chain is not remodeled after uptake of an ether lipid precursor (see below).
As expected on the basis of other papers, plasmalogen deficiency in cultured fibroblasts could 
be successfully overcome by supplementation with hexadecylglycerol and batyl alcohol. Remarkably, 
also HDG attached to a phosphate at the sn-3 position, was able to permeate the fibroblasts and 
proved at least as efficient for recovery of plasmalogen levels as the other two compounds. 
Astonishingly, three-day-treatment did not only restore plasmalogens to the amounts reached in 
controls but, moreover, exceeded the control values by far. HDG-treated fibroblasts, for example, 
exhibited as much as 22% plasmenylethanolamines out of all detected phosholipids compared with
∼12% measured in control cells. In contrast, 72-hour-treatment of DAPAT-deficient CHO cells with 20 
µM HDG – an equal concentration as used in the present study – was reported to result in PL-PE 
levels slightly above the wild type value (Nagan et al., 1998). Another publication describes the 
restoration of plasmenylethanolamines to only about 65% of the control level after 24-hour-
supplementation of Zellweger fibroblasts with 20 µg/ml (∼63 µM) HDG (Styger et al., 2002) – a higher 
concentration, but shorter time than applied here. The results obtained for RCDP patient cells 
indicate that uptake and utilization of plasmalogen precursors in human fibroblasts occur extremely 
efficiently, if the respective substances are added in micromolar concentrations for a sufficient time. 
Notably, the cells take up and most probably utilize more ether lipid precursors than they synthesize 
themselves in the absence of any culture medium supplement. This may indicate that plasmalogens 
are highly favorable lipids for fibroblasts, as the cells apparently engulf as much of these compounds
as is available.
Lipidomic analysis of the sn-1 chain after treatment showed clearly that the composition of the 
precursor molecule determines the sn-1 composition of the final plasmalogen. Treatment with HDG 
(a C16 glycerol ether) only restored plasmenylethanolamines with a C16:0 chain, whereas 
supplementation with BA led to a strong increase in C18:0 plasmalogens. This result is in line with the 
observations of Mankidy and collaborators, who describe a similar determination effect at sn-1 in a 
DAPAT-deficient CHO cell line after application of several precursor substances (Mankidy et al., 
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2010). Evidently, the sn-1 moiety does not undergo any rearrangement after uptake of the precursor 
as opposed to the sn-2 chain, which has been shown to be deacylated and, subsequently, reacylated 
with other fatty acid residues (Mankidy et al., 2010). Surprisingly, in a mouse model of mild RCDP
(see chapter 1.2.2), treatment with batyl alcohol increased the blood levels of all plasmalogen 
species (C16:0, C18:0 and C18:1). Possibly, a multicellular organism enables a more complex and 
versatile utilization of a supplemented precursor molecule. Alternatively, the precursor might, e.g. by 
some feedback mechanism, stimulate further synthesis of ether lipids, which to a low extent is 
possible in this Pex7 hypomorphic mouse. In the latter case, one would hypothesize that in a 
complete knockout the full spectrum at the sn-1 position cannot be recovered. 
So far, it is not known, whether the composition of the sn-1 moiety has any effect on the function of 
plasmalogens. Therefore, there might be no physiological difference between supplementing cells 
with HDG or with BA in order to regain plasmalogens. However, if a regeneration of the full spectrum 
of different plasmenylethanolamines is intended, at least in culture, a mixture of precursors each
containing either C16:0, C18:0 or C18:1 has to be applied. Although BA and HDG provide highly 
valuable tools for cell culture work, it remains questionable, whether these substances are 
potentially capable of curing RCDP. BA treatment of the Pex7 hypomorphic mouse and of RCDP 
patients resulted in elevated RBC plasmalogen levels10 (Braverman et al., 2010; Das et al., 1992). 
However, an appreciable relief of the symptoms has neither been achieved in mice nor in human 
patients. On the one hand, the reason for this could be the inability of the used precursors to cross 
the blood-brain barrier. For this to change, the sn-2 and sn-3 positions would have to be modified in 
order to increase the permeability of the applied molecules. On the other hand, a dietary 
alkylglycerol supplement could be subject to degradation in the liver, before it reaches peripheral 
tissues and restores plasmalogen levels there. The enzyme alkylglycerol monooxygenase (AGMO), 
which is most abundant in the liver and the small intestine (Watschinger et al., 2010), cleaves the O-
alkyl-ether bond preferably in alkylglycerols with C16, C15 and C18 chains, rendering BA and HDG 
perfect substrates for this enzyme. In order to allow for effective long-term benefits of dietary ether 
lipid supplementations, it may, therefore, be necessary to bypass the activity of AGMO. This could be 
accomplished, for example, by the introduction of a 1’-double bond (as it is present in plasmalogens), 
which abolishes the activity of the monooxygenase (Taguchi and Armarego, 1998). The examination 
of the capability of such or a similar substance to restore plasmalogen levels and – in consequence –
the application in vivo are desirable future aims. 
Upon mass spectrometric phospholipid analyses of untreated and precursor (BA, HDG)-treated 
control and RCDP patient cells, it became apparent that the cells employ compensatory mechanisms 
in response to the loss and gain of ether lipids. In patient fibroblasts with hardly any 
plasmenylethanolamines, the level of phosphatidylethanolamine was greatly increased. In contrast, 
after the regeneration of plasmalogens by precursors, the amount of PE declined significantly so that 
the total portion of ethanolamine phospholipids was kept constant at about 25-30% of total 
phospholipids in every case. A similar compensatory mechanism involving PE has also been observed 
in CHO cells deficient in ether lipid biosynthesis (Honsho et al., 2008; Nagan et al., 1997; Nagan et al., 
1998). Additionally, increased PE – together with a slight rise in sphingomyelin amount, which was 
not detected in RCDP fibroblasts in the course of my thesis work – accounts for a loss of PL-PEs in 
synaptosomes and synaptosome membrane rafts in the DAPAT knockout mouse model (Brodde, 
10 These results were also confirmed by a recent clinical study involving mild and severe RCDP patients 
(International Standard Randomized Controlled Trial Number 44820021: Alcohol supplementation in rhizomelic 
chondrodysplasia punctata in the Netherlands).
Discussion
69
2009; Rodemer et al., 2003). Thus, cells apparently require a certain, predetermined proportion of 
ethanolamine phospholipids, which is maintained under every condition. 
GPI-anchored proteins are highly important molecules for mammals, as they perform a 
multitude of fundamental tasks in virtually all kinds of tissues. However, in spite of extensive 
scientific studies, the biological function of a 1-alkyl chain in the lipid moiety of the GPI anchor, which 
is present in a large subset of GPI-anchored proteins, is not clear yet. Since this ether bond-
containing lipid has been shown to be dependent on the peroxisomal pathway of ether lipid 
synthesis, now a variety of useful tools – namely model systems that are deficient in this kind of 
pathway – is available to study the significance of the alkyl chain. Based on the chemical nature of 
the GPI anchor, the assumption is obvious that the ether-containing chain might play a role in 
membrane anchoring of the respective proteins. Yet, the present study offers – by 
immunofluorescent staining methods – the first proof that in human and murine ether lipid 
biosynthesis-deficient cells an endogenous GPI-anchored protein can be efficiently transported to 
the outer surface of the plasma membrane, similar as in the respective control cells. Singh and 
collaborators additionally showed that, after transfection with a plasmid expressing GPI-anchored 
alkaline phosphatase, this protein could be detected at the surface of CHO-K1 cells, a CHO cell line 
deficient in peroxisomes, and in DAPAT-defective murine macrophages (Singh et al., 1994). Given 
that Thy-1 has been shown to at least in part contain an alkyl chain in its GPI anchor in mice and in 
rats (Homans et al., 1988; Jayachandran, 2007), all these results suggest that correct targeting of GPI-
anchored proteins can take place even in the absence of ether lipids and that a 1-alkyl chain in the 
lipid moiety of the anchor is not essential for the membrane localization of these proteins. 
Apparently, the utilization of diacylglycerol can – at least in case of Thy-1 – fully compensate for the 
inability to synthesize alkylacylglycerol in terms of membrane anchorage. 
Apart from membrane trafficking and anchoring, there are several other possibilities, how 
deficient ether lipid biosynthesis may affect GPI-anchored proteins. A further question that was 
addressed in my thesis was, whether the deficiency in ether lipid synthesis has any influence on the 
general level of GPI-anchored proteins in fibroblasts of human RCDP patients. Rodemer and 
collaborators reported the reduction of a GPI-anchored protein, but also of other membrane-raft-
associated proteins in DAPAT-deficient mice (Rodemer et al., 2003). Therefore, there are two 
conceivable ways, how a defect in ether lipid synthesis might change the amounts of GPI-anchored 
proteins. First, the inability to integrate an alkyl chain could interfere with normal GPI-protein 
expression e.g. by some feedback mechanism. More likely, however, as plasmalogens have been 
demonstrated to be essential components of raft domains (Pike et al., 2002), these might be 
structurally changed upon loss of plasmalogens and – as a consequence – the stability and half life of 
raft proteins could be dysregulated resulting in altered total amounts of these proteins. Surprisingly, 
in human RCDP fibroblasts, no consistent alterations in the relative amounts of raft proteins 
compared with non-raft proteins were observed. Instead, individual proteins showed several changes 
in certain cell lines. Contrary to what had been described for the DAPAT ko mouse, in human patient 
fibroblasts, no decrease in the amount of flotillin-1 could be seen. Some cell lines even exhibited 
increased levels, as judged from western blot analysis of total cellular extracts. However, since also 
the amount of the non-raft protein transferrin receptor, which previously had been shown to be 
grossly normal in DAPAT- and AGPS-deficient human fibroblasts (Thai et al., 2001), appeared 
elevated, this is likely to be due to an increased membrane surface compared with other cell lines. 
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The latter assumption is also supported by the fact that in membrane-enriched fractions all cell lines 
showed rather equal levels of flotillin-1 and transferrin receptor. 
Concerning the amounts of GPI-anchored proteins, both studied proteins, Thy-1 and CD55, displayed 
a similar pattern; protein levels were normal, as compared to control cell lines, in mild RCDP 
fibroblasts. However, a severe decrease was detected in one (RCDP 2-2), but not the other (RCDP 1-
2) severely deficient cell line. As this reduction does not seem to generally affect raft proteins (mind 
the unaltered levels of flotillin-1), this result rather suggests that the inability to synthesize 
alkylacylglycerol for the lipid moiety of the anchor is responsible for the dysregulated levels of GPI-
anchored proteins in this specific cell line. Nevertheless, the question remains, why these changes 
can only be observed in one out of two cell lines derived from severe RCDP patients, especially 
because these two lines showed very similar levels of residual plasmalogens in mass spectrometric 
analyses. Seemingly, ether lipid deficiency alone is not sufficient to induce such differences, but 
another factor, e.g. a certain genetic modifier, is required. 
In addition to GPI-anchored proteins, also the gap-junctional transmembrane protein connexin 43, 
which is targeted to membrane rafts as well (Schubert et al., 2002), was found to be reduced in the 
severely affected cell line RCDP 2-2. In contrast to the two GPI-anchored proteins, a decrease in Cx43 
levels was, even if less drastical, also noticed in a second severe RCDP cell line. Interestingly, a similar 
depletion of Cx43 was also observed in embryonic fibroblasts derived from DAPAT knockout mice 
(Rodemer et al., 2003). Connexin 43 is known to play important roles in a variety of tissues, e.g. it has 
recently been shown to be crucial for the development of the lung (Nagata et al., 2009). However, 
the protein exerts its main functions in the mammalian heart, where it is the predominant connexin
subtype. Cx43 is essential for normal ventricular function and the development of the heart outflow 
tract and is present in mammalian cardiomyocytes already in early stages of fetal development (Van 
Kempen et al., 1996). As a consequence, mice lacking Cx43 show a broad range of severe cardiac 
deficiencies and die soon after birth (Reaume et al., 1995; Ya et al., 1998). In humans, disturbances in 
Cx43 expression have been suggested to account for arrhythmia, a life-threatening condition of 
abnormal electrical activity in the heart (Poelzing and Rosenbaum, 2004). Remarkably, the patient, 
who cell line RCDP 2-2, showing the most severe reduction in Cx43 levels, originated from, suffered 
from a lethal congenital heart defect called tetralogy of Fallot (TOF) (Nimmo et al., 2010), a 
condition, in which Cx43 levels and distribution have been reported to be altered (Kolcz et al., 2005). 
Another possible connection between plasmalogen deficiency and Cx43 dysregulation is presented 
by Styger and collaborators: In their studies on fibroblasts derived from Zellweger patients, they 
observed a significant increase in number and signaling activity of β-adrenoceptors, which proved to 
be dependent on impaired ether lipid biosynthesis (Styger et al., 2002). Stimulation of β-
adrenoceptors is known to upregulate the level of Cx43 expression (Salameh et al., 2009; Xia et al., 
2009). The increase in adrenoceptor number and activity in ether lipid-deficient cells might therefore 
reflect an effort to compensate for the reduction of Cx43 in such cells. 
Currently, it cannot be judged unambiguously, whether the reduction of Cx43 that was determined in 
RCDP 2-2 fibroblasts is a secondary effect of the heart defect observed in this patient, or whether 
plasmalogen depletion causes Cx43 deficiency, finally resulting in heart malformations. However, the 
fact that decreased Cx43 was also observed in DAPAT ko mouse fibroblasts and does not seem to be 
restricted to heart tissue, strengthens the latter hypothesis. Even if heart defects are not a fully 
penetrant symptom assigned to RCDP, there is a striking accumulation of RCDP patients suffering 
from heart disease, indicating an association between the two. In addition to Nimmo and 
collaborators, several other groups report RCDP cases with TOF (Akgun et al., 2010; Kazemian et al., 
2009), arrhythmia (Dilli et al., 2008) and other kinds of heart lesions (Fourie, 1995; Pascolat et al., 
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2003). Still, substantial knowledge about the contribution of the lack of ether lipids to these cardiac 
deficiencies is missing. Also, it remains unclear, why some RCDP patients develop heart defects and 
others do not. However, connexin 43 and associated signaling pathways may constitute a good 
starting point to study the role of ether lipids in heart development or functioning.
As discussed above, GPI-anchored proteins are efficiently incorporated into the membrane in 
spite of a deficiency in ether lipid synthesis. However, immunofluorescence studies cannot shed light 
on the correct localization to raft subdomains. Therefore, DRM isolation experiments were employed 
to examine the raft association of GPI-anchored proteins in RCDP fibroblasts and led to interesting 
results. Although Thy-1 mostly co-migrated with the raft marker flotillin-1 in sucrose density gradient 
centrifugation, it appeared to a larger extent also in fractions of slightly higher density in cells derived 
from both mild and severe RCDP patients. This implies that GPI-anchored proteins are still targeted 
to detergent-resistant membrane domains even under conditions of ether lipid deficiency, but the 
membrane surroundings seem somehow changed as compared to cells of healthy control patients. 
However, in part, this behavior was also observed for flotillin-1. Generally, the obtained results are in 
line with those of other groups, who did not discover any changes in DRM association of endogenous 
and transfected GPI-anchored proteins in ether lipid synthesis-deficient CHO cells (Honsho et al., 
2008; Kanzawa et al., 2009). Both of these studies, though, conducted plain detergent extraction 
instead of a density gradient and thus only offer two fractions – one DRM-associated and one non-
DRM fraction – in their figures. Therefore, slight changes as observed in the present experiment, are 
not revealed. Membrane rafts constitute highly fragile structures that can easily be disturbed by 
several influences like cellular aging (Inomata et al., 2006), cholesterol sequestration (Persaud-Sawin 
et al., 2009; Sheets et al., 1999) and others. In that respect, it is not surprising that a depletion of 
plasmalogens and alkylacyl-GPI anchors induces changes in these subdomains, especially in view of 
the fact that plasmalogens are strongly enriched in membrane rafts (Pike et al., 2002). 
Similar to what was discussed above, it remains unresolved, whether the detected differences should 
be assigned to the changed GPI anchor lipid moiety or to the lack of plasmalogens. Targeting the first 
possibility, a change from alkylacylglycerol to diacylglycerol might influence the association of GPI-
anchored proteins with rafts or a certain class of rafts. Apparently, the lack of alkylacylglycerol does 
not generally abolish the connection of GPI-anchored proteins with raft microdomains, as happens in 
case of shortened fatty acid chains in the lipid moiety (Benting et al., 1999). However, there are 
several subtypes of these domains and different raft markers are known to be targeted to one, but 
not the other kind of raft (Schnitzer et al., 1995; Wilson et al., 2004). The slight modification of the 
lipid moiety could change the affinity of a GPI-anchored protein for one or the other subtype, e.g. in 
this case the preference of the protein would be shifted towards a subdomain of somewhat higher 
density. On the other hand, the depletion of plasmalogens is very likely to cause changes in the 
composition and maybe also the assembly of membrane rafts, as is also hypothesized by Rodemer 
and collaborators based on their observations in tissues derived from the DAPAT ko mouse (Rodemer 
et al., 2003). Studies on plasmalogen-deficient cell and model membranes report alterations in 
membrane fluidity and gel-to-liquid transition (Hermetter et al., 1989; Paltauf, 1994). Similarly, in the 
plasmalogen-deficient fibroblasts used in this diploma thesis, a changed density of membrane rafts 
due to the forced modification of phospholipid composition is conceivable. A slight general change of 
raft microdomains would also account for the fact that not only GPI-anchored proteins, but in some 
cases also the raft marker flotillin-1 exhibited the shift to higher density fractions. Additionally to 
these considerations, several publications also record impairments in cholesterol transport and 
distribution in ether lipid-deficient mammalian cells (Munn et al., 2003; Rodemer et al., 2003; Thai et 
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al., 2001). Whether this is a consequence of raft alterations or rather causes them, is not known. 
However, these observations substantiate the assumption of changes in lipid rafts due to the lack of 
ether lipids. 
Finally, it is to notice that also a minor reduction of plasmalogen levels seems to be sufficient to 
cause the raft modifications observed in this study. This can be concluded from the similar floating 
behavior, especially of the GPI-anchored protein Thy-1, in cells affected by mild and severe ether 
lipid deficiency. Due to the enrichment of plasmalogens in membrane rafts, these subdomains might 
be more vulnerable than other parts of the membrane in case of a reduction of plasmalogens. Taken 
together and in view of the current literature, all obtained results point towards an important role of 
plasmalogens in membrane rafts. Nevertheless, further experiments are needed to confirm the 
proposed correlations and to elucidate the exact effect of ether lipid deficiency on these membrane 
domains. 
In order to quantify motor deficits, which are apparent upon long-term observations in the DAPAT ko 
mouse, two different behavioral test paradigms, both of which are routinely used for the assessment 
of motor behavior, were applied. Although the results of Rotarod tests were not statistically 
significant, a clear trend of DAPAT ko mice to fall off the treadmill earlier than wild type controls was 
visible. The lack of significance can on the one hand be attributed to relatively low n-numbers (for 
this type of test) and high variability in the performance especially of wild type mice. On the other 
hand, not only motor skills, but also other factors like motivation, anxiety or general sensory abilities 
(smell, vision, etc.) are supposed to contribute to the performance on the Rotarod apparatus even 
after several training sessions. However, in combination with the balance beam experiments, which 
proved highly significant impairments in DAPAT ko mice, these results indicate a clear motor 
deficiency of ether lipid-deficient mice in comparison with wild type littermates. This is in agreement 
with the observations of Teigler and collaborators, who rudimentarily reported deficits of DAPAT ko 
mice in Rotarod and vertical pole tests. In the latter publication, though, these impairments were
assigned to cerebellar abnormalities (Teigler et al., 2009). Nevertheless, there might also be other 
reasons accounting for a motor impairment in these mice. Several recent publications associate poor 
performances on either the balance beam or the Rotarod with neuromuscular dysfunction (Gomez et 
al., 1997; Pelkonen and Yavich, 2011; Shi et al., 2010). Thus, some defect in the formation of the 
neuromuscular junction (NMJ) in ether lipid-deficient mice is conceivable. In the present study, NMJ 
formation was examined in a cell culture model of differentiated myotubes stimulated with agrin. 
The number of resulting acetylcholine receptor clusters proved unchanged in myotubes derived from 
DAPAT ko animals as compared to wt myotubes; in contrast, size of the clusters appeared smaller in 
the mutants. As the results presented here, so far, refer to only one quantified experiment, it is not 
surprising that statistical significance was not reached. However, further experiments and 
optimization of myoblast cultivation will be carried out to confirm the detected changes. 
Generally, the formation of the neuromuscular synapse is a highly complicated process, whose 
molecular basis has not been fully elucidated yet. MuSK is known to be a key player in this process, as 
it is able to induce or at least stabilize clustering of acetylcholine receptors, the main prerequisite for 
NMJ formation (Glass et al., 1996; Hoch, 2003). Mice lacking MuSK do not form neuromuscular 
junctions and die immediately after birth (DeChiara et al., 1996). Interestingly, two groups showed 
independently that, after agrin stimulation, MuSK is partitioned into membrane rafts (Stetzkowski-
Marden et al., 2006; Zhu et al., 2006). Furthermore, other main components of the process, e.g. the 
scaffolding protein rapsyn, were identified as raft proteins and even acetylcholine receptor clustering 
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itself takes place in these specialized membrane domains (Pato et al., 2008; Zhu et al., 2006). Zhu and 
collaborators actually demonstrated that, upon disruption of rafts by the cholesterol extracting agent 
methyl-β-cyclodextrin or the chemical agent PDMP11, MuSK signaling and the phosphorylation of 
acetylcholine receptors, which initiates cluster formation (Borges and Ferns, 2001; Wallace, 1995), 
are almost fully abolished (Zhu et al., 2006). Therefore, a disturbance of membrane rafts evoked by 
the lack of plasmalogens or altered distribution of GPI-anchored proteins might easily account for an 
impaired formation of the neuromuscular junction and could be the cause of the observed reduction 
in size of agrin-elicited acetylcholine receptor clusters in DAPAT-deficient myotubes. However, 
additional experiments are required to reveal the role of ether lipids in the multifactorial process of 
NMJ formation. In a further step, the situation in vivo, e.g. in an ether lipid-deficient mouse model, 
should be studied. In contrast to the myoblast culture experiments, where only the postsynaptic part 
of the synapse is targeted, this would also involve the presynaptic, i.e. the neuronal, side of the 
neuromuscular junction. To date, it is not known, how ether lipid deficiency influences innervation of 
the muscle. Many proteins mediating contact or signaling between nerve and muscle are associated 
with membrane rafts or GPI anchors – as an example, the GPI-anchored ephrin A-2 has been 
localized to the neuromuscular synapse (Lai and Ip, 2003). The effect of the lack of ether lipids on all 
these factors can only be speculated on at the moment. Finally, as an ultimate goal, possible 
disturbances need to be correlated with the phenotype in the respective mouse model and in human 
patients to identify the molecular origin of the many severe symptoms observed in RCDP. 
Considering all aspects covered in the present diploma thesis, it seems very likely that an inability to 
synthesize ether lipids has serious consequences for membrane rafts contributing to the severe 
phenotype in mammals lacking these lipids. Although some of the data can be considered as 
preliminary, the entirety of the presented results demonstrates a key role of ether lipids in these 
membrane domains. However, the exact underlying mechanisms are still unclear rendering rafts 
under conditions of ether lipid deficiency a topic of major interest for further scientific work. Future 
experiments should address the questions, how raft formation, stability and functionality are 
affected by the lack of ether lipids. Also, the influence on individual raft proteins – with special 
attention to GPI-anchored proteins – has to be further clarified to ultimately elucidate the relation 
between membrane raft alterations and the symptoms in ether lipid-deficient individuals.
11 D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol
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